WO2024007055A1 - Method of production of modified phage and method of treatment using same - Google Patents
Method of production of modified phage and method of treatment using same Download PDFInfo
- Publication number
- WO2024007055A1 WO2024007055A1 PCT/AU2023/050622 AU2023050622W WO2024007055A1 WO 2024007055 A1 WO2024007055 A1 WO 2024007055A1 AU 2023050622 W AU2023050622 W AU 2023050622W WO 2024007055 A1 WO2024007055 A1 WO 2024007055A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phage
- bacteria
- species
- infection
- modified
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 119
- 238000004519 manufacturing process Methods 0.000 title claims description 11
- 238000011282 treatment Methods 0.000 title abstract description 64
- 241000894006 Bacteria Species 0.000 claims abstract description 227
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 86
- 230000009089 cytolysis Effects 0.000 claims abstract description 32
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 22
- 238000012258 culturing Methods 0.000 claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 238000001243 protein synthesis Methods 0.000 claims abstract description 16
- 230000014616 translation Effects 0.000 claims abstract description 16
- 241001515965 unidentified phage Species 0.000 claims abstract description 12
- 229960002227 clindamycin Drugs 0.000 claims description 115
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 114
- 208000015181 infectious disease Diseases 0.000 claims description 70
- 230000001580 bacterial effect Effects 0.000 claims description 46
- 230000002101 lytic effect Effects 0.000 claims description 31
- 229960004099 azithromycin Drugs 0.000 claims description 29
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 29
- 230000000644 propagated effect Effects 0.000 claims description 29
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 28
- 230000003115 biocidal effect Effects 0.000 claims description 26
- 208000035143 Bacterial infection Diseases 0.000 claims description 24
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 22
- 229940123573 Protein synthesis inhibitor Drugs 0.000 claims description 21
- 239000000007 protein synthesis inhibitor Substances 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 16
- 238000001066 phage therapy Methods 0.000 claims description 15
- 229960003276 erythromycin Drugs 0.000 claims description 14
- 230000002147 killing effect Effects 0.000 claims description 13
- 101710126949 Lysin Proteins 0.000 claims description 12
- 241000186359 Mycobacterium Species 0.000 claims description 11
- 241000589516 Pseudomonas Species 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 241000194033 Enterococcus Species 0.000 claims description 9
- 241000191940 Staphylococcus Species 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 9
- 241000894007 species Species 0.000 claims description 9
- 241000588626 Acinetobacter baumannii Species 0.000 claims description 7
- 241000186216 Corynebacterium Species 0.000 claims description 7
- 241000607734 Yersinia <bacteria> Species 0.000 claims description 7
- 241000607142 Salmonella Species 0.000 claims description 6
- 201000009890 sinusitis Diseases 0.000 claims description 6
- 241000193163 Clostridioides difficile Species 0.000 claims description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 5
- 238000011200 topical administration Methods 0.000 claims description 5
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 4
- 241000589601 Francisella Species 0.000 claims description 4
- 241000589248 Legionella Species 0.000 claims description 4
- 208000032376 Lung infection Diseases 0.000 claims description 4
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 4
- 241001134656 Staphylococcus lugdunensis Species 0.000 claims description 4
- 241000194017 Streptococcus Species 0.000 claims description 4
- 238000002648 combination therapy Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 206010040872 skin infection Diseases 0.000 claims description 4
- 241000589291 Acinetobacter Species 0.000 claims description 3
- 241000193403 Clostridium Species 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- 231100000019 skin ulcer Toxicity 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 36
- 229940088710 antibiotic agent Drugs 0.000 description 36
- 239000001974 tryptic soy broth Substances 0.000 description 26
- 108010050327 trypticase-soy broth Proteins 0.000 description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 25
- 230000035945 sensitivity Effects 0.000 description 20
- 238000012360 testing method Methods 0.000 description 19
- 230000012010 growth Effects 0.000 description 18
- 238000011534 incubation Methods 0.000 description 17
- 239000011780 sodium chloride Substances 0.000 description 17
- 235000002639 sodium chloride Nutrition 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 210000004877 mucosa Anatomy 0.000 description 14
- 230000035899 viability Effects 0.000 description 14
- 239000000523 sample Substances 0.000 description 13
- 241000588724 Escherichia coli Species 0.000 description 12
- 239000000872 buffer Substances 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 239000006150 trypticase soy agar Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 230000002195 synergetic effect Effects 0.000 description 9
- 239000002028 Biomass Substances 0.000 description 8
- 241000702202 Siphoviridae Species 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 208000035473 Communicable disease Diseases 0.000 description 7
- 230000002458 infectious effect Effects 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 108700010839 phage proteins Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- 241001337904 Gordonia <angiosperm> Species 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 108010059993 Vancomycin Proteins 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 229960003165 vancomycin Drugs 0.000 description 6
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 6
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000701553 Myoviridae Species 0.000 description 5
- 241000823609 Staphylococcus aureus subsp. aureus RN4220 Species 0.000 description 5
- 208000026935 allergic disease Diseases 0.000 description 5
- 230000007815 allergy Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000006161 blood agar Substances 0.000 description 5
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 241000606125 Bacteroides Species 0.000 description 4
- 238000009631 Broth culture Methods 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- 241000194031 Enterococcus faecium Species 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 241000588748 Klebsiella Species 0.000 description 4
- 239000006137 Luria-Bertani broth Substances 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 229960003022 amoxicillin Drugs 0.000 description 4
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 4
- 210000002421 cell wall Anatomy 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000008029 eradication Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000001543 one-way ANOVA Methods 0.000 description 4
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 208000031729 Bacteremia Diseases 0.000 description 3
- 208000008960 Diabetic foot Diseases 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000006142 Luria-Bertani Agar Substances 0.000 description 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 3
- 241000702072 Podoviridae Species 0.000 description 3
- 241000186429 Propionibacterium Species 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 229940124350 antibacterial drug Drugs 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- -1 carrier Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 238000011284 combination treatment Methods 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 229960001484 edetic acid Drugs 0.000 description 3
- 210000001214 frontal sinus Anatomy 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229960003085 meticillin Drugs 0.000 description 3
- 238000011201 multiple comparisons test Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229960000268 spectinomycin Drugs 0.000 description 3
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000005919 time-dependent effect Effects 0.000 description 3
- 210000001635 urinary tract Anatomy 0.000 description 3
- 208000019206 urinary tract infection Diseases 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 206010001076 Acute sinusitis Diseases 0.000 description 2
- 206010009137 Chronic sinusitis Diseases 0.000 description 2
- 241000989055 Cronobacter Species 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 108010059378 Endopeptidases Proteins 0.000 description 2
- 102000005593 Endopeptidases Human genes 0.000 description 2
- 241000588921 Enterobacteriaceae Species 0.000 description 2
- 241000194036 Lactococcus Species 0.000 description 2
- 239000006156 Mannitol salt agar Substances 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000002815 broth microdilution Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000011278 co-treatment Methods 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- CKMXAIVXVKGGFM-UHFFFAOYSA-N p-cumic acid Chemical compound CC(C)C1=CC=C(C(O)=O)C=C1 CKMXAIVXVKGGFM-UHFFFAOYSA-N 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000004708 ribosome subunit Anatomy 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- QQJLHRRUATVHED-UHFFFAOYSA-N tramazoline Chemical compound N1CCN=C1NC1=CC=CC2=C1CCCC2 QQJLHRRUATVHED-UHFFFAOYSA-N 0.000 description 2
- 229960001262 tramazoline Drugs 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 231100000747 viability assay Toxicity 0.000 description 2
- 238000003026 viability measurement method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 1
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- 241001024600 Aggregatibacter Species 0.000 description 1
- 241001135756 Alphaproteobacteria Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000118325 Autographivirinae Species 0.000 description 1
- 241000589941 Azospirillum Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241001266956 Bacteroides phage B124-14 Species 0.000 description 1
- 241000406197 Bacteroides phage B40-8 Species 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 206010005940 Bone and joint infections Diseases 0.000 description 1
- 244000205725 Boronia megastigma Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000206605 Brochothrix Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241001453380 Burkholderia Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010065839 Capreomycin Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000863012 Caulobacter Species 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 241000186650 Clavibacter Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 241001135900 Corynebacterium phage BFK20 Species 0.000 description 1
- 241000513245 Corynebacterium phage P1201 Species 0.000 description 1
- 241000702221 Cystoviridae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 241001600129 Delftia Species 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 241000807859 Enterococcus phage EFAP-1 Species 0.000 description 1
- 241000776099 Enterococcus phage SAP6 Species 0.000 description 1
- 241000410382 Enterococcus phage phiEF24C Species 0.000 description 1
- 241000557996 Enterococcus phage phiEf11 Species 0.000 description 1
- 241000943509 Enterococcus phage phiFL1A Species 0.000 description 1
- 241000943514 Enterococcus phage phiFL2A Species 0.000 description 1
- 241000943512 Enterococcus phage phiFL3A Species 0.000 description 1
- 241000943515 Enterococcus phage phiFL4A Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000495778 Escherichia faecalis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- TZXKOCQBRNJULO-UHFFFAOYSA-N Ferriprox Chemical compound CC1=C(O)C(=O)C=CN1C TZXKOCQBRNJULO-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000589565 Flavobacterium Species 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 241000626621 Geobacillus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241001281676 Gordonia phage GAL1 Species 0.000 description 1
- 241000357954 Gordonia phage Smoothie Species 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000206596 Halomonas Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001070681 Kayvirus Species 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000588752 Kluyvera Species 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000724188 Lactococcus phage Species 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241001293415 Mannheimia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000192701 Microcystis Species 0.000 description 1
- 241000588771 Morganella <proteobacterium> Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241001508003 Mycobacterium abscessus Species 0.000 description 1
- 241001285096 Mycobacterium phage Baee Species 0.000 description 1
- 241000447006 Mycobacterium phage Hamulus Species 0.000 description 1
- 241000447011 Mycobacterium phage Muddy Species 0.000 description 1
- 241000507433 Mycobacterium phage Solon Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000995057 Mycobacterium virus Mozy Species 0.000 description 1
- 241001208555 Mycobacterium virus Omega Species 0.000 description 1
- 241000852935 Mycobacterium virus Ramsey Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 241000520272 Pantoea Species 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241000192001 Pediococcus Species 0.000 description 1
- 241000118313 Picovirinae Species 0.000 description 1
- 241000530769 Planktothrix Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000283080 Proboscidea <mammal> Species 0.000 description 1
- 241000170840 Propionibacterium phage PA6 Species 0.000 description 1
- 241000346609 Propionibacterium phage PAD20 Species 0.000 description 1
- 241000346681 Propionibacterium phage PAS50 Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000519590 Pseudoalteromonas Species 0.000 description 1
- 241001499750 Pseudomonad phage gh-1 Species 0.000 description 1
- 241001641497 Pseudomonas phage B3 Species 0.000 description 1
- 241001163331 Pseudomonas phage Bf7 Species 0.000 description 1
- 241000435301 Pseudomonas phage EL Species 0.000 description 1
- 241000754464 Pseudomonas phage F10 Species 0.000 description 1
- 241000754439 Pseudomonas phage F8 Species 0.000 description 1
- 241000189348 Pseudomonas phage LBL3 Species 0.000 description 1
- 241000541273 Pseudomonas phage LKA1 Species 0.000 description 1
- 241000541283 Pseudomonas phage LKD16 Species 0.000 description 1
- 241000189364 Pseudomonas phage LMA2 Species 0.000 description 1
- 241000222629 Pseudomonas phage LUZ19 Species 0.000 description 1
- 241000296418 Pseudomonas phage OBP Species 0.000 description 1
- 241000754452 Pseudomonas phage PA11 Species 0.000 description 1
- 241000345855 Pseudomonas phage PAJU2 Species 0.000 description 1
- 241001481578 Pseudomonas phage PB1 Species 0.000 description 1
- 241000616090 Pseudomonas phage PT2 Species 0.000 description 1
- 241001553300 Pseudomonas phage PT5 Species 0.000 description 1
- 241001320177 Pseudomonas phage PaP1 Species 0.000 description 1
- 241001588240 Pseudomonas phage SN Species 0.000 description 1
- 240000006477 Pseudomonas phage phi-2 Species 0.000 description 1
- 241000930917 Pseudomonas phage phi13 Species 0.000 description 1
- 241000484871 Pseudomonas phage phi15 Species 0.000 description 1
- 241000295851 Pseudomonas phage phi2954 Species 0.000 description 1
- 241000398382 Pseudomonas phage phi297 Species 0.000 description 1
- 241000509380 Pseudomonas phage phi8 Species 0.000 description 1
- 241000617481 Pseudomonas phage phiIBB-PF7A Species 0.000 description 1
- 241001184708 Pseudomonas phage phiKMV Species 0.000 description 1
- 241000805893 Pseudomonas phage phikF77 Species 0.000 description 1
- 241001428540 Pseudomonas virus D3 Species 0.000 description 1
- 241000398389 Pseudomonas virus PMG1 Species 0.000 description 1
- 241001131732 Pseudomonas virus PaP3 Species 0.000 description 1
- 241000702217 Pseudomonas virus phi6 Species 0.000 description 1
- 241000438345 Pseudomonas virus phiKZ Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 1
- URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241001135312 Sinorhizobium Species 0.000 description 1
- 241001660101 Sodalis Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 241001329015 Spounavirinae Species 0.000 description 1
- 241001613945 Staphylococcus phage 2638A Species 0.000 description 1
- 241001613948 Staphylococcus phage 66 Species 0.000 description 1
- 241000121786 Staphylococcus phage IME-SA2 Species 0.000 description 1
- 241000634306 Staphylococcus phage P954 Species 0.000 description 1
- 241001234601 Staphylococcus phage PVL Species 0.000 description 1
- 241000204593 Staphylococcus phage S13' Species 0.000 description 1
- 241000204572 Staphylococcus phage S24-1 Species 0.000 description 1
- 241000009028 Staphylococcus phage SA1 Species 0.000 description 1
- 241001480830 Staphylococcus phage SAP-2 Species 0.000 description 1
- 241000677981 Staphylococcus phage TEM126 Species 0.000 description 1
- 241001457051 Staphylococcus phage phi11 Species 0.000 description 1
- 241000008793 Staphylococcus phage phi2958PVL Species 0.000 description 1
- 241000554961 Staphylococcus phage phiNM Species 0.000 description 1
- 241000554957 Staphylococcus phage phiNM3 Species 0.000 description 1
- 241001572748 Staphylococcus phage phiPVL-CN125 Species 0.000 description 1
- 241000450817 Staphylococcus phage tp310-2 Species 0.000 description 1
- 241000450818 Staphylococcus phage tp310-3 Species 0.000 description 1
- 241000624640 Staphylococcus prophage phiPV83 Species 0.000 description 1
- 241001399465 Staphylococcus virus 108PVL Species 0.000 description 1
- 241001105570 Staphylococcus virus 13 Species 0.000 description 1
- 241000543698 Staphylococcus virus 187 Species 0.000 description 1
- 241001613917 Staphylococcus virus 29 Species 0.000 description 1
- 241001613930 Staphylococcus virus 37 Species 0.000 description 1
- 241001586731 Staphylococcus virus 3a Species 0.000 description 1
- 241001613944 Staphylococcus virus 42e Species 0.000 description 1
- 241001186872 Staphylococcus virus 44AHJD Species 0.000 description 1
- 241001613923 Staphylococcus virus 52a Species 0.000 description 1
- 241001613942 Staphylococcus virus 53 Species 0.000 description 1
- 241001613919 Staphylococcus virus 55 Species 0.000 description 1
- 241001613943 Staphylococcus virus 69 Species 0.000 description 1
- 241001613927 Staphylococcus virus 71 Species 0.000 description 1
- 241001435321 Staphylococcus virus 77 Species 0.000 description 1
- 241000520053 Staphylococcus virus 80alpha Species 0.000 description 1
- 241000609849 Staphylococcus virus 85 Species 0.000 description 1
- 241001613921 Staphylococcus virus 88 Species 0.000 description 1
- 241001613916 Staphylococcus virus 92 Species 0.000 description 1
- 241001613925 Staphylococcus virus 96 Species 0.000 description 1
- 241000945539 Staphylococcus virus CNPH82 Species 0.000 description 1
- 241001613926 Staphylococcus virus EW Species 0.000 description 1
- 241001137784 Staphylococcus virus G1 Species 0.000 description 1
- 241001232319 Staphylococcus virus IPLA35 Species 0.000 description 1
- 241001232400 Staphylococcus virus IPLA88 Species 0.000 description 1
- 241000239110 Staphylococcus virus K Species 0.000 description 1
- 241000949504 Staphylococcus virus PH15 Species 0.000 description 1
- 241000352142 Staphylococcus virus SAP26 Species 0.000 description 1
- 241000543700 Staphylococcus virus Twort Species 0.000 description 1
- 241001613616 Staphylococcus virus X2 Species 0.000 description 1
- 241001105562 Staphylococcus virus phi12 Species 0.000 description 1
- 241001526669 Staphylococcus virus phiETA Species 0.000 description 1
- 241000004493 Staphylococcus virus phiETA2 Species 0.000 description 1
- 241000004494 Staphylococcus virus phiETA3 Species 0.000 description 1
- 241000212110 Staphylococcus virus phiMR11 Species 0.000 description 1
- 241000260449 Staphylococcus virus phiMR25 Species 0.000 description 1
- 241000886175 Staphylococcus virus phiSLT Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000192707 Synechococcus Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000975215 Thalassomonas Species 0.000 description 1
- 241000589596 Thermus Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241001070682 Twortvirus Species 0.000 description 1
- 102100028298 Vacuolar protein sorting-associated protein VTA1 homolog Human genes 0.000 description 1
- 101710111280 Vacuolar protein sorting-associated protein VTA1 homolog Proteins 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- OZKXLOZHHUHGNV-UHFFFAOYSA-N Viomycin Natural products NCCCC(N)CC(=O)NC1CNC(=O)C(=CNC(=O)N)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC1=O)C2CC(O)NC(=N)N2 OZKXLOZHHUHGNV-UHFFFAOYSA-N 0.000 description 1
- 108010015940 Viomycin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 241000589634 Xanthomonas Species 0.000 description 1
- 241000204366 Xylella Species 0.000 description 1
- 241000312514 Yersinia phage phiR1-37 Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- PENDGIOBPJLVBT-HMMOOPTJSA-N abt-773 Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@]1(C)OC\C=C\C=1C=C2C=CC=CC2=NC=1)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O PENDGIOBPJLVBT-HMMOOPTJSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 230000003214 anti-biofilm Effects 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000001420 bacteriolytic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960004602 capreomycin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229950010329 cethromycin Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960003266 deferiprone Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229940118764 francisella tularensis Drugs 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 230000007446 host cell death Effects 0.000 description 1
- 230000007412 host metabolism Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000012092 latex agglutination test Methods 0.000 description 1
- 229940062711 laureth-9 Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 229960003128 mupirocin Drugs 0.000 description 1
- 229930187697 mupirocin Natural products 0.000 description 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229950003776 protoporphyrin Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000013643 reference control Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- IWQPOPSAISBUAH-VOVMJQHHSA-M sodium;2-[[(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyl-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylheptanoyl]amino]ethanesulfonate Chemical compound [Na+].C1C[C@@H](O)[C@@H](C)[C@@H]2CC[C@]3(C)[C@@]4(C)C[C@H](C(C)=O)/C(=C(C(=O)NCCS([O-])(=O)=O)/CCCC(C)C)[C@@H]4C[C@@H](O)[C@H]3[C@]21C IWQPOPSAISBUAH-VOVMJQHHSA-M 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960003250 telithromycin Drugs 0.000 description 1
- LJVAJPDWBABPEJ-PNUFFHFMSA-N telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000007195 tryptone soya broth Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229950001272 viomycin Drugs 0.000 description 1
- GXFAIFRPOKBQRV-GHXCTMGLSA-N viomycin Chemical compound N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)C[C@@H](N)CCCN)CNC(=O)[C@@H]1[C@@H]1NC(=N)N[C@@H](O)C1 GXFAIFRPOKBQRV-GHXCTMGLSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/06—Lysis of microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10111—Myoviridae
- C12N2795/10121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/44—Staphylococcus
- C12R2001/445—Staphylococcus aureus
Definitions
- the present disclosure relates to the field of bacteriophage therapy, particularly in the circumstance of the treatment of a drug-resistant bacteria which is also bacteriophage non-sensitive (insensitive). Among other things, the present disclosure relates to a method of producing modified bacteriophage that are capable of infecting and causing lysis of a parent host bacteria that is insensitive to the unmodified bacteriophage.
- PRIORITY DOCUMENT [0002] The present application claims priority from Australian Provisional Patent Application No.
- bacteria antibiotic resistance include either a reduction in the affinity of the antibiotic agent to bind to its bacterial target protein or a reduction in the bacterial intracellular drug concentration.
- the former is primarily caused by the emergence of mutation(s) in the genes encoding the target protein of the antibiotic, while the latter is mainly achieved through alterations in the plasma membrane permeability, expression of degradation/modification enzymes, or overexpression of efflux pumps.
- bacteria can increase their tolerance and resistance to antibiotics through the formation of a biofilm, which then acts as a natural barrier to prevent the absorption of antibacterial drugs such as antibiotics.
- the biofilm drug-resistance mechanism is different from that of individual bacteria and, compared with planktonic bacteria, this drug-resistance mechanism can increase the bacterial antibiotic tolerance 10- to 1000-fold, and is one of the main causes of current bacterial drug resistance.
- the extracellular polymeric substance (EPS) secreted by bacteria one of the main components of a biofilm, forms a dense and negatively charged natural barrier, which prevents the penetration of antibiotics and other antibacterial drugs into the membrane, thus reducing the concentration of drugs inside the membrane. Additionally, the lack of enough nutrients inside of the biofilm will inhibit the bacterial metabolic activity, and subsequently promote bacteria to enter a dormant state, making them more resistant to the drug during the reproduction period as many antibiotics rely on proliferation of the bacteria for effectiveness.
- Phage were first applied to anti-bacterial infection treatments in clinics over 100 years ago, and they were utilised specifically to kill and target bacterial hosts causing infection. Due to the discovery and widespread use of antibiotic agents, the use of phage has diminished. However, due to the ongoing problem of drug-resistant bacteria (and especially, the multidrug-resistant (MDR) bacteria), phage therapy has now returned to the spotlight. Further, it is now more fully appreciated that phage possess unique advantages that may mean that phage targeting specific pathogenic bacteria can be isolated to meet clinical needs more quickly than the development of novel antibacterial drugs. Phage are also very abundant in nature, lack cross-resistance with antibiotics, and are highly specific (compared to antibiotics).
- phage can also be effective in disrupting bacterial biofilms, and offer enormous potential to serve as the basis of therapies providing an effective and sustainable solution for the treatment of bacteria, including treatment for superbugs and refractory MDR bacterial infections.
- the utility of phage in the clinic has been limited. Part of the reason for the lack of adoption of phage therapy is the narrow antibacterial spectrum of many phage. Further, many clinical isolates are resistant to known phage. In such conditions, a patient may have a considerable waiting period until a suitable phage is available for treating their specific bacterial infection and/or there are no phage suitable to infect a particular resistant bacterial infection.
- the present disclosure provides a method of producing a modified phage, said method comprising the steps of: (i) treating a host bacteria insensitive to a selected phage strain (ie a phage non-sensitive, or phage insensitive, or phage resistant bacteria) with a suitable amount of the said phage strain and at least one antibacterial agent comprising protein synthesis inhibitor activity, and culturing the bacteria for a period and under conditions suitable for the phage to infect the bacteria and replicate to generate progeny phage; and (ii) recovering and expanding progeny phage which are phage with a modified capability to infect and cause lysis of said host bacteria.
- a host bacteria insensitive to a selected phage strain ie a phage non-sensitive, or phage insensitive, or phage resistant bacteria
- a suitable amount of the said phage strain and at least one antibacterial agent comprising protein synthesis inhibitor activity culturing the bacteria for a period and under conditions suitable for the phage
- the host bacteria is a sample of a bacteria causative of an infection being suffered by a subject
- the phage is a phage selected from a "phage bank" and is one that is normally regarded as infectious for the host bacteria if not for the circumstance that the bacteria has become insensitive to the phage (ie is phage non-sensitive).
- the progeny phage have a modified capability to infect and cause lysis of said host bacteria, and may therefore be useful in treating the infection in the subject.
- the present disclosure provides a method of treating a bacterial infection in a subject, said method comprising the steps of: 1. obtaining a sample of a bacteria causative of an infection in said subject, 2.
- the bacteria with a suitable amount of a selected phage strain to which the bacteria is insensitive (ie the bacteria is phage non-sensitive) and at least one antibacterial agent comprising protein synthesis inhibitory activity, and culturing the bacteria for a period and under conditions suitable for the phage to infect the bacteria and replicate to generate progeny phage; 3. recovering and expanding progeny phage which are phage with a modified capability to infect and cause lysis of said host bacteria; and 4. administering to the subject an effective amount of the progeny phage, or a further propagated form thereof, to treat the infection.
- a suitable amount of a selected phage strain to which the bacteria is insensitive ie the bacteria is phage non-sensitive
- at least one antibacterial agent comprising protein synthesis inhibitory activity
- the present disclosure provides a modified phage produced in accordance with the method of the first aspect, or a further propagated form thereof.
- the present disclosure provides a pharmaceutical composition comprising a modified phage produced in accordance with the method of the first aspect, or a further propagated from thereof, optionally in combination with at least one pharmaceutically acceptable additive, carrier, diluent and/or excipient.
- the present disclosure provides the use of a modified phage produced in accordance with the method of the first aspect, or a further propagated form thereof, in the manufacture of a medicament for treating an infection in a subject.
- the present disclosure provides a modified phage, produced in accordance with the method of the first aspect, or a further propagated form thereof, for treating an infection in a subject.
- the present disclosure provides a method of killing bacteria, said method comprising contacting the bacteria with a modified phage produced in accordance with the method of the first aspect or a further propagated form thereof.
- the present disclosure provides an isolated phage lysin protein (an endolysin) derived from a modified phage produced in accordance with the method of the first aspect.
- Figure 1 provides the results of experimentation to determine any synergy between phage and various antibiotic agents on bacterial viability.
- Protein synthesis inhibitors PSI
- E erythromycin
- C clindamycin
- Az azithromycin
- V cell wall actives amoxicillin
- CI3 vancomycin
- Significant reductions were observed, compared to treatment with phage or antibiotic alone, for all combinations of phage and PSIs.
- Figure 2 provides the results of experiments to assess whether enhanced bacterial killing by the combination of clindamycin and phage was dose dependent.
- Black bars represent S. aureus ATCC51650 and CI11 treated with medium (TSB), J- Sa36 (Sa36) or clindamycin (1 ⁇ 2 MIC or 0.1 ⁇ g/ml) as control.
- Grey bars represent S. aureus ATCC51650 and CI11 treated with J-Sa36 combined with different concentrations of clindamycin;
- Figure 3 provides results showing that the phage J-Sa36, Sa83 or Sa87 combined with clindamycin reduces the viability of ATCC51650 and CI11 biofilms. In particular, the reduction of biofilm viability of S.
- aureus ATCC51650 or CI11 were grown in the absence (control) or presence of J- Sa36 (Sa36; MOI 0.2) or 1 ⁇ 2 MIC clindamycin for 3.5 hours, followed by the addition of 1 ⁇ 2 MIC clindamycin (Sa36+ 1 ⁇ 2 MIC clindamycin added at 3.5 hrs) or phage J-Sa36 (1 ⁇ 2 MIC clindamycin + J- Sa36 added at 3.5 hrs) with OD600 recorded at 3.5 (black bars) and 24 hours (grey bars); (C, D) ATCC51650 and CI11 respectively were pre-treated for different times with either 1 ⁇ 2 MIC clindamycin (black bar) or TSB only (grey) before J-Sa36 (MOI 0.2) was added at 1, 2, 3, 3.5, 4, 6 and 24 hrs.
- Colony Forming Unit (CFU) counts CFU/ml (A) and biofilm biomass ( ⁇ m 3 / ⁇ m 2 ) (B) of a fresh piece of rat sinonasal mucosa from rats treated with 0.5 x 10 10 PFU/ml Sa87 in combination with 1 ⁇ 2 MIC clindamycin [Sa87 + C], 0.5 x 10 10 PFU/ml Sa87 in combination with 1 ⁇ 2 MIC azithromycin [Sa87 + Az], 0.5 x 10 10 PFU/ml Sa87 [Sa87], 1 ⁇ 2 MIC clindamycin [C], 1 ⁇ 2 MIC azithromycin [Az], saline [Saline].
- CFU Colony Forming Unit
- FIG. 6 provides graphical results showing that the combination of S. aureus phage and 1 ⁇ 2 MIC clindamycin kills non-sensitive S. aureus strains: (A) S. aureus C43 treated with APTC-SA-2 and 1 ⁇ 2 MIC clindamycin; (B) S.
- aureus C330 treated with APTC-SA-2 and 1 ⁇ 2 MIC clindamycin
- C S. aureus ATCC25923 treated with APTC-SA-2 and 1 ⁇ 2 MIC clindamycin
- D S. aureus C285 treated with APTC-SA-12 and 1 ⁇ 2 MIC clindamycin
- E S. aureus C319 treated with APTC-SA-12 and 1 ⁇ 2 MIC clindamycin
- F S. aureus ATCC25923 treated with APTC-SA-12 and 1 ⁇ 2 MIC clindamycin. Significance was determined compared to untreated control. Data expressed as mean ⁇ SEM for three independent experiments.
- Figure 7 provides the results of bactericidal activity tests performed on exit phage. The exit phage's bactericidal activity was tested in its own host, S.
- Figure 8 shows graphical results of tests for the exit phage specificity and lytic activity.
- FIG. 9 provides characterising (stability and growth) results for entry phage and exit phage:
- FIG. 10 shows the results of a representative PHEARLESS Assay to determine the lytic activity of exit phage produced in accordance with the method of the disclosure.
- aureus with lytic phage in combination with a sub-inhibitory concentration (MIC) of erythromycin, clindamycin and azithromycin can significantly reduce the growth of the bacteria.
- Characterisation of the phage isolated after the treatment (“exit phage") then, surprisingly, revealed that the phage were able to re-infect their "parent” bacterial host without the need (or “help") of the antibiotic, and moreover, with up to a 1000-fold higher level of lytic activity as compared to that of the "entry phage" (ie the initial phage used).
- the dosage of exit phage to have significant antibacterial effects against the parent bacterial host was less than 1000 th the dosage of the entry phage and the entry phage could only infect the parent bacteria in the presence of protein synthesis inhibitor (PSI) antibiotics whilst the exit phage could infect the parent bacterial strains also in the absence of PSI antibiotics.
- PSI protein synthesis inhibitor
- the stability (ie temperature and pH stability) of the exit phage and their growth curve were, however, substantially unchanged and, in particular, showed no significant difference when compared with the corresponding entry phage.
- the burst size of the exit phage was higher than the entry phage (ie the burst size (calculated at 30min) for entry phage APTC- SA-2 was 30 PFUs/infected cell; while for exit phage APTC-SA-2-43, the burst size was 40 PFUs/infected cell, and for exit phage APTC-SA-2-330, 42 PFUs/infected cell.
- the burst size was 14 PFUs/infected cell, in comparison to burst sizes of 33 and 38 PFUs/infected cell, respectively, for the exit phage APTC-SA-12-C285 and exit phage APTC-SA- 12-319).
- exit phage showed a significantly lower BIM frequency compared to entry phage.
- the Applicants have identified a novel method for the production of a modified phage, derived from a phage for which a host bacterial strain is or has become insensitive (ie the bacteria is phage non- sensitive), which is capable of infecting the host bacteria strain and, preferably, also shows an enhanced level of lytic activity with a reduction in dosage required to achieve bacterial eradication, an increase in the burst size of the exit phage, and/or achieves a reduction in the frequency of emergence of bacteriophage insensitive mutants (BIM) when bacteria are treated with the exit phage compared to when they are treated with the parent entry phage (in the presence of sub-inhibitory PSI antibiotics).
- BIM bacteriophage insensitive mutants
- the present disclosure provides a method of producing a modified phage, said method comprising the steps of: (i) treating a host bacteria insensitive to a selected phage strain (ie a phage non-sensitive, or phage insensitive, or phage resistant bacteria) with a suitable amount of the said phage strain and at least one antibacterial agent comprising protein synthesis inhibitor activity, and culturing the bacteria for a period and under conditions suitable for the phage to infect the bacteria and replicate to generate progeny phage; and (ii) recovering and expanding progeny phage which are phage with a modified capability to infect and cause lysis of said host bacteria.
- a host bacteria insensitive to a selected phage strain ie a phage non-sensitive, or phage insensitive, or phage resistant bacteria
- a suitable amount of the said phage strain and at least one antibacterial agent comprising protein synthesis inhibitor activity culturing the bacteria for a period and under conditions suitable for the phage
- the present disclosure provides a method of producing phage with improved lytic activity against a phage insensitive bacteria, by exposing the insensitive host bacterium to a selected infecting phage and an agent having protein synthesis inhibitory activity, and producing a phage with improved lytic activity against the insensitive bacteria.
- the host bacteria used in step (i) may be any phage insensitive bacteria strain, but preferably, will be a phage insensitive bacteria strain of medical and/or veterinary significance.
- the host bacteria is selected from the group consisting of Staphylococcus species, Streptococcus species, Enterococcus species, Corynebacterium species, Bacteroides species, Bacillus species, Yersinia species, Legionella species, Francisella species, Salmonella species, Gordonia species, Mycobacterium species, Acinetobacter species, Clostridium species, Pseudomonas species, and Enterobacteriaceae species. [0032] In some embodiments, the host bacteria is selected from the group consisting of S. aureus, S. epidermidis, S.
- the host bacteria is a drug-resistant bacteria, such as an antibiotic- resistant bacteria, and especially a multidrug-resistant (MDR) bacteria or superbug, such as methicillin-resistant Staphylococcus aureus (MRSA).
- MDR multidrug-resistant
- the host bacteria is a bacteria having a characteristic of the ability to form a biofilm.
- the host bacteria is an S.
- aureus bacteria may otherwise be of a species such as Acinetobacter baumannii (which can cause life-threatening infections in the blood, lungs, urinary tract and in wounds), Clostridium difficile (which can cause life-threatening infections and damage to the intestinal mucosa), Pseudomonas aeruginosa (which is a common cause of chronic airway infections in cystic fibrosis patients, and which can cause serious infections in the ear, skin, blood and parts of the body following surgery), and Enterobacteriaceae species (such as E.coli, E. faecium such as vancomycin-resistant E. faecium, and Klebsiella spp. such as K. pneumoniae).
- Acinetobacter baumannii which can cause life-threatening infections in the blood, lungs, urinary tract and in wounds
- Clostridium difficile which can cause life-threatening infections and damage to the intestinal mucosa
- Pseudomonas aeruginosa which is
- the host bacteria is selected from the group consisting of multidrug resistant (MDR) strains of bacteria.
- MDR multidrug resistant
- examples of MDR strains of A. baumannii, E. coli, Klebsiella spp. and P. aeruginosa are also particularly well known and widespread.
- the host bacteria used in step (i) may, preferably, be a clinical isolate and, in particular, a clinical isolate from a subject requiring treatment for a bacterial infection; that is, the host bacteria is a sample of the bacteria causative of an infection being suffered by a subject.
- the host bacteria is a clinical isolate from a bacterial infection characterised by the presence of a bacterial biofilm.
- the bacteria are gram-negative bacteria, while in some other embodiments, the bacteria are gram-positive bacteria.
- suitable host bacteria include bacteria from the following species: Bacillus (eg Bacillus anthracis), Brochothrix, Corynebacterium, Enterococcus, Fingoldia (eg Fingoldia magna), Francisella (eg Francisella tularensis) Geobacillus, Gordonia, Lactobacillus, Leuconostoc, Lactococcus, Legionella, Listeria, Microcystis, Mycobacterium (eg Mycobacterium abscessus, Mycobacterium tuberculosis), Nocardia, Pediococcus, Propionibacterium, Rhodococcus, Staphylococcus (eg Staphylococcus aureus; Staphylococcus epidermidis, Staphylococcus lugdunensis) Streptococcus, Aeromonas, Azospirillum, Aggregatibacter, Bacteroides,
- the bacteria are selected from bacteria of the following genus: Citrobacter Cronobacter
- the host bacteria is treated in step (i) with a suitable amount of a phage that would normally be regarded as infectious for the bacteria if not for the circumstance that the particular bacterial strain concerned has become insensitive to the phage.
- the phage may be a phage that is normally infectious for S. aureus.
- Staphylococcus phage examples include phage from the Myoviridae, Siphoviridae, Podoviridae, Picovirinae, Spounavirinae, and Twortlikevirus families.
- Staphylococcus phage examples include Staphylococcus phage SA1, Staphylococcus phage phi13, Staphylococcus phage phi2958PVL, Staphylococcus phage phiETA2, Staphylococcus phage phiETA3, Staphylococcus phage phiMR11, Staphylococcus phage phiMR25, Staphylococcus phage phiNM, Staphylococcus phage phiNM3, Staphylococcus phage phiPVL108, Staphylococcus phage phiPVL-CN125, Staphylococcus phage phiSauS-IPLA35, Sta
- the phage used in step (i) may be selected from examples of Enterococcus phage such as those from the Siphoviridae and Myoviridae families.
- Enterococcus phage include Enterococcus phage EFAP-1, Enterococcus phage phiEf11, Enterococcus phage phiEF24C, Enterococcus phage phiFL1A, Enterococcus phage phiFL2A, Enterococcus phage phiFL3A, Enterococcus phage phiFL4A, and Enterococcus phage SAP6.
- the phage used in step (i) may be selected from examples of Corynebacterium phage such as those of the Siphoviridae family.
- Particular examples of Corynebacterium phage include Corynebacterium phage BFK20 and Corynebacterium phage P1201.
- the phage used in step (i) may be selected from examples of Pseudomonas phage including phage of the Podoviridae, Autographivirinae, Siphoviridae, Podoviridae, Myoviridae and Cystoviridae families.
- Pseudomonas phage include Pseudomonas phage H105/1, Pseudomonas phage LKA1, Pseudomonas phage B3, Pseudomonas phage D3, Pseudomonas phage F10, Pseudomonas phage F116, Pseudomonas phage F8, Pseudomonas phage gh-1, Pseudomonas phage LBL3, Pseudomonas phage LKD16, Pseudomonas phage LMA2, Pseudomonas phage LUZ19, Pseudomonas phage PA11, Pseudomonas phage PAJU2, Pseudomonas phage PaP3, Pseudomonas phage PB1, Pseudomona
- the phage used in step (i) may be selected from examples of Bacteroides phage include phage of the Siphoviridae family such as Bacteroides phage B40-8 and Bacteroides phage B124-14.
- the phage used in step (i) may be selected from examples of Propionibacterium phage include phage of the Siphoviridae family such as Propionibacterium phage PA6, Propionibacterium phage PAD20, and Propionibacterium phage PAS50.
- the phage used in step (i) may be selected from examples of Mycobacterium include phage of the Siphoviridae and Myoviridae families.
- Mycobacterium phage include Mycobacterium phage Muddy, Mycobacterium phage Baee, Mycobacterium phage Girr, Mycobacterium phage Hamulus, Mycobacterium phage Mozy, Mycobacterium phage Omega, Mycobacterium phage Ramsey, Mycobacterium phage Soul22, and Mycobacterium phage St Annes.
- the phage used in step (i) may be selected from examples of Yersinia such as those of the Myoviridae family. Particular examples of Yersinia phage include Yersinia phage phiR1-37.
- the phage used in step (i) may be selected from examples of Gordonia such as those of the Siphoviridae family. Particular examples of Gordonia phage include Gordonia phage Smoothie.
- Further examples of suitable specific phage for use in step (i), and their respective bacterial "pair" (ie host bacteria) are shown in Table 1 below. [0056] Table 1 Bacteriophage Host genus Enterococcus phage vB_EfaP_Ef6.3 Enterococcus
- the phage may be selected from available stocks of phage such as may be found in a "phage bank", or identified by screening natural sources of phage.
- the phage used to treat the host bacteria are referred to as the "entry phage”.
- the phage will be provided in an amount corresponding to a multiplicity of infection (MOI) value in the range of 0.05 to 2.0, more preferably about 0.5 to 1.2, and most preferably, of about 1.0.
- MOI multiplicity of infection
- the MOI may be 1.0 or more, 0.5 or more, 0.1 or more, or 0.001 or more, or less than 1.0, less than 0.1, or less than 0.01.
- the antibacterial agent used to treat the host bacteria in step (i) comprises protein synthesis inhibitor activity.
- Protein synthesis inhibitors may act via a mechanism of an interruption of peptide chain elongation, the blocking of the decoding site (A site) of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins.
- Antibacterial agents such as PSI antibiotics are well known to those skilled in the art.
- the antibacterial agent comprising protein synthesis inhibitory activity comprises an agent which binds to the 50S ribosomal subunit and inhibits protein synthesis by preventing peptide chain elongation. Examples include macrolides such as clindamycin, erythromycin, clarithromycin and azithromycin.
- the antibacterial agent comprising protein synthesis inhibitory activity comprises an agent that can inhibit protein synthesis by blocking the A site of the 30S ribosomal subunit.
- examples include kanamycin and streptomycin.
- protein synthesis inhibitors suitable for use in step (i) include spectinomycin, tetracycline, clindamycin, azithromycin, kanamycin, gentamicin, netilmicin, linezolid, chloramphenicol, capreomycin, mupirocin, dactinomycin, telithromycin, neomycin, lincomycin, fusidic acid, cethromycin, viomycin, sisomycin, puromycin and streptomycin.
- the host bacteria is treated in step (i) with an amount of the antibacterial agent that is equal to or greater than the MIC, for example 2 x MIC, or 1 x MIC. [0063] In some embodiments, the host bacteria is treated in step (i) with a sub-inhibitory amount of at least one antibacterial agent.
- the sub-inhibitory amount will be in the range of about 0.125 to 0.95 x MIC (minimum inhibitory concentration), more preferably about 0.125 to 0.65 x MIC and most preferably, about 0.5 x MIC ("1 ⁇ 2 MIC"). Other concentrations are, however, also contemplated.
- the present disclosure provides a method of producing a modified phage, said method comprising the steps of: (i) treating a host bacteria insensitive to a selected phage strain (ie a phage non-sensitive, or phage insensitive, or phage resistant bacteria) with a suitable amount of the said phage strain and a sub- inhibitory amount of at least one antibacterial agent comprising protein synthesis inhibitor activity, and culturing the bacteria for a period and under conditions suitable for the phage to infect the bacteria and replicate to generate progeny phage; and (ii) recovering and expanding progeny phage which are phage with a modified capability to infect and cause lysis of said host bacteria.
- a host bacteria insensitive to a selected phage strain ie a phage non-sensitive, or phage insensitive, or phage resistant bacteria
- a suitable amount of the said phage strain and a sub- inhibitory amount of at least one antibacterial agent comprising protein synthesis inhibitor activity and cul
- the treatment with the antibacterial agent may be performed concurrently with the phage treatment, before treatment with the phage, and/or after treatment with the phage.
- the treatment with the antibacterial agent is performed before the treatment with the phage (ie before the phage is added) in what is effectively a pre-treatment with the antibacterial agent.
- the pre-treatment with the antibacterial agent may be commenced up to 10 hours, more preferably up to 6 hours, more preferably up to 4 hours, more preferably up to 3 hours, prior to contacting the host bacteria with the entry phage.
- the phage may be added first, then followed by the addition of the antibacterial agent.
- the host bacteria treated in accordance with step (i) are cultured for a period and under conditions suitable for the phage to infect the bacteria and replicate to generate progeny phage.
- the culture will be performed on standard growth media for 24 hours at 37 o C.
- the progeny phage are also referred to as the "exit phage”.
- Exit phage may be readily purified from the culture of step (i), if desired, by standard methodologies known to those skilled in the art including, for example, a purification process comprising centrifugation of the culture (to remove residual bacteria and bacterial cell walls etc.
- exit phage progeny phage
- exit phage that have a modified capability to infect and cause lysis and killing of the host bacteria
- exit phage which show a modified, enhanced, level of bactericidal activity against the host bacteria or "parent" used in step (i) relative to the entry phage
- the number of phage ie the number of phage particles is increased
- a method of treating a subject requiring treatment for a bacterial infection or for storage in, for example, a phage bank are recovered and propagated to expand the number of phage (ie the number of phage particles is increased) for subsequent use in, for example, a method of treating a subject requiring treatment for a bacterial infection or for storage in, for example, a phage bank.
- This may involve one or more steps (preferably, two or more steps) of culturing the host bacteria in the presence of the exit phage, or in other words, one or more steps of passaging the exit phage through the host bacteria.
- These culturing/passaging steps preferably do not include any treatment with the antibacterial agent as used in step (i) of the method, but may do so. Otherwise, the exit phage may be propagated by culturing/passaging with other sensitive bacteria to expand the number of phage. Phage particles that are present after these culturing/passaging steps represent modified exit phage that are capable of infecting and causing lysis of the host bacteria.
- these exit phage may undergo one or more selection or analysis steps including, but not limited to: identifying exit phage with markedly enhanced lytic activity (eg to identify modified phage capable of infecting the parent bacteria only, but with at least a 500-fold or, more preferably, 1000-fold higher level of lytic activity; identifying exit phage with stability and/or growth (replication) characteristics that are substantially unchanged from that of the entry phage, except for a higher burst size; and/or identifying exit phage which encode and produce a lysin protein with markedly enhanced lytic activity which may involve, for example, assessing the relative lytic activity of the lysin protein produced by the modified phage (eg by expressing an isolated nucleic acid molecule encoding the lysin protein in a host bacteria: see for example the PHEARLESS assay described in the examples hereinafter) or through the sequencing of at least a lysin-encoding nucleotide sequence within the exit phage genome.
- the method of the first aspect may be performed in a multiple (parallel) format where different entry phage are separately used to treat different samples of host bacteria to generate different progeny exit phage; and the use of the optional one or more selection or analysis steps may then be used to identify a preferred exit phage from amongst the separately generated exit phage candidates.
- the exit phage may be further propagated using the host bacteria or other sensitive phage to further expand the number of phage, such as for the purpose of storage in a phage bank.
- the method of the first aspect may be advantageous inasmuch as the use of repeated steps for the generation of modified phage may be avoided.
- step (i) preferably consists of no more than three steps, or no more than two steps, and more preferably only a single step of treating the insensitive host bacteria with a suitable amount of the selected phage strain and at least one antibacterial agent, and culturing the bacteria for a period and under conditions suitable for the phage to infect the bacteria and replicate to generate progeny phage.
- the steps of culturing/passaging are preferably not conducted using the host bacteria in combination with at least the antibacterial agent that was used in step (i) or, more preferably, any other antibacterial agent comprising protein synthesis inhibitor activity.
- the method of the first aspect may produce a modified exit phage to which the host bacteria has been re-sensitised, and which may be of use in (for example) treating a subject requiring treatment for a bacterial infection (ie in a phage therapy).
- the method of the first aspect may be used to produce a modified exit phage which, unlike the selected entry phage, is capable of infecting and causing lysis of a host bacteria (such as a clinical isolate) causative of an infection being suffered by a subject.
- the method of the first aspect is for producing a modified phage for use in a phage therapy of a subject's infection, and comprises the steps of: (i) treating a host bacteria that has been isolated from the said subject and which is insensitive to a selected phage strain (ie a phage non-sensitive bacteria) with a suitable amount of the said phage strain and at least one antibacterial agent comprising protein synthesis inhibitory activity, and culturing the bacteria for a period and under conditions suitable for the phage to infect the bacteria and replicate to generate progeny phage; (ii) recovering and expanding progeny phage which are phage with a modified capability to infect and cause lysis of said host bacteria; and (iii) providing the modified phage in a pharmaceutical composition for administration to the said subject.
- a selected phage strain ie a phage non-sensitive bacteria
- the amount of the antibacterial agent comprising protein synthesis inhibitory is activity is a sub-inhibitory amount.
- Such embodiments enable a "personalised" approach to phage therapy which may be employed, for example, where a phage with an effective level of bactericidal activity against a bacteria causative of an infection in a subject, has either not been identified or is not readily available.
- the method may enable the selection of an available phage that would normally be regarded as infectious for the bacteria if not for the circumstance that the particular bacterial strain concerned has become insensitive to the phage, and to use that phage as an entry phage from which to produce a modified exit phage that may then enable an effective phage therapy of the infection in the subject.
- the present disclosure provides a method of treating a bacterial infection in a subject, said method comprising the steps of: 1. obtaining a sample of a bacteria causative of an infection in said subject, 2.
- the bacteria with a suitable amount of a selected phage strain to which the bacteria is insensitive (ie the bacteria is phage non-sensitive) and at least one antibacterial agent comprising protein-synthesis inhibitory activity, and culturing the bacteria for a period and under conditions suitable for the phage to infect the bacteria and replicate to generate progeny phage; 3. recovering and expanding progeny phage which are phage with a modified capability to infect and cause lysis of said host bacteria; and 4. administering to the subject an effective amount of the progeny phage, or a further propagated form thereof, to treat the infection.
- a suitable amount of a selected phage strain to which the bacteria is insensitive ie the bacteria is phage non-sensitive
- at least one antibacterial agent comprising protein-synthesis inhibitory activity
- the present disclosure provides a method of treating a bacterial infection in a subject, the method comprising producing phage with improved lytic activity against a phage insensitive bacteria by exposing the insensitive host bacterium to a selected infecting phage and an agent having protein synthesis inhibitory activity and treating the infection with an effective amount of the phage with improved lytic activity.
- the present disclosure provides a method of treating a bacterial infection in a subject, said method comprising the steps of: 1. obtaining a sample of a bacteria causative of an infection in said subject, 2.
- the bacteria with a suitable amount of a selected phage strain to which the bacteria is insensitive (ie the bacteria is phage non-sensitive) and a sub-inhibitory amount of at least one antibacterial agent comprising protein-synthesis inhibitory activity, and culturing the bacteria for a period and under conditions suitable for the phage to infect the bacteria and replicate to generate progeny phage; 3. recovering and expanding progeny phage which are phage with a modified capability to infect and cause lysis of said host bacteria; and 4. administering to the subject an effective amount of the progeny phage, or a further propagated form thereof, to treat the infection.
- a suitable amount of a selected phage strain to which the bacteria is insensitive ie the bacteria is phage non-sensitive
- a sub-inhibitory amount of at least one antibacterial agent comprising protein-synthesis inhibitory activity comprising protein-synthesis inhibitory activity
- the method of the second aspect may, particularly, be used to treat an infection in the subject which is not responding to antibiotic-based therapy (thereby indicating that the infectious bacteria is antibiotic drug-resistant) and/or treatment with phage (thereby indicating that the infectious bacteria is phage resistant or phage insensitive).
- the bacterial sample may be obtained from (eg isolated from), for example, a suitable body sample from the subject such as blood, urine, faecal sample, swab, or a tissue biopsy (eg a biopsy from a tissue at the site of infection). Bacteria present in the body sample may be isolated and expanded according to any of the standard methodologies known to those skilled in the art.
- the bacteria may optionally be identified by using standard methodologies including microscopy techniques, tests such as latex agglutination tests (see, for example, Essers L., J Clin Microbiol 12(5):641-643, 1980), MALDI and/or 16 S rRNA gene sequencing such as is well known to those skilled in the art.
- a phage that would normally be regarded as infectious for the bacteria may be selected from, for example, a phage bank for use as the "entry phage", however more typically, the selected phage will be a phage previously employed in a phage therapy on the subject (which was unsuccessful) or to which the causative bacteria has been found to be insensitive in, for example, a standard in vitro phage sensitivity test.
- the bacteria may be treated with the phage and antibacterial agent as described above in relation to the method of the first aspect. The treatment of the bacteria with the antibacterial agent is typically performed before the phage treatment.
- the step of recovering and expanding the progeny "exit phage" may be carried out as described above in relation to the method of the first aspect.
- the modified exit phage may also be further propagated using, for example, a sensitive bacterial strain, as required (eg for storage in a phage bank).
- the modified exit phage (or a further propagated form thereof) will typically be provided as a pharmaceutical composition comprising the phage in combination with at least one pharmaceutically acceptable carrier, diluent and/or excipient.
- the modified exit phage may be administered to the subject by any suitable route such as topical administration (eg for treatment of a surface wound), intramuscular administration (im) (eg by injection), intravenous administration (iv) (especially systemic infusion), oral administration or airway administration (eg by rinsing, nebulisation, spraying into the nose and paranasal sinuses and into the lungs in pulmonary administration).
- topical administration eg for treatment of a surface wound
- intramuscular administration eg by injection
- intravenous administration iv
- oral administration eg by rinsing, nebulisation, spraying into the nose and paranasal sinuses and into the lungs in pulmonary administration.
- the modified phage (or a further propagated form thereof) may be administered with one or more additional phage strain(s) (ie in a "phage cocktail") which may contribute to the effectiveness of the phage therapy in treating the infection, particularly in the case of a polymicrobial infection (ie where more than one bacteria strain is present in the infection).
- the modified phage (or a further propagated form thereof) may be used in a combination therapy with a suitable antibacterial agent.
- the method of the second aspect may be used to treat a bacterial infection in a subject, and especially a bacterial infection caused by bacteria showing drug-resistance and/or which is phage insensitive.
- the method of the second aspect may be used to treat an infection in a subject caused by methicillin-resistant Staphylococcus aureus (MRSA) (eg a skin or lung infection, diabetic foot ulcer, sinus infection or sepsis), A. baumannii (eg an infection of the blood (bacteremia), lungs or urinary tract, or a wound infection by A. baumannii), C. difficile (eg a colon infection), P. aeruginosa (eg a lung infection, bacteremia, bone and joint infections, post-surgery infection, diabetic foot ulcers, sinus infection, ear infection), MDR strains of E.coli (eg an urinary tract infection (UTI)), an E.
- MRSA methicillin-resistant Staphylococcus aureus
- the method of the second aspect may be used to treat sinusitis or rhinosinusitis (acute rhinosinusitis and chronic rhinosinusitis) which is commonly caused by S. aureus and/or P. aeruginosa.
- sub-inhibitory amount refers to an amount (concentration) of an antibacterial agent which is below that required to detectably inhibit the growth and replication of a particular bacteria.
- the sub-inhibitory amount is a non-lethal amount for the particular bacteria.
- minimum inhibitory concentration is to be understood as it is to those skilled in the art. Therefore, as used herein, the term refers to the lowest amount (concentration) of an antibacterial agent that detectably inhibits the growth of a particular bacteria.
- phage non-sensitive phage insensitive
- phage resistant are used interchangeably to describe a characteristic of a particular bacteria to be insensitive to a certain phage or phages, such that phage(s) when contacted with the bacteria is unable to substantially infect and/or cause lysis of the bacteria (eg as may be detected by standard in vitro phage sensitivity test where lysis zones are assessed after spotting of phage onto a bacterial lawn on a standard petri dish or plate, and overnight culture).
- Such bacteria may be partially or fully resistant to the particular phage or phages.
- phage contacted with "sensitive" bacteria will infect and/or cause lysis of the bacteria.
- lysis refers to a process whereby, for example, a phage or chemical agent causes the breaking down of the wall or membrane of a cell such as a bacterial cell leading to cell death.
- the modified exit phage may show enhanced “lytic activity", meaning that the modified phage has an enhanced (increased) capability to cause lysis and/or killing of the host bacteria as compared to the entry phage.
- This lytic activity may be achieved, wholly or in part, by phage proteins known as "endolysins" (lysins) which are peptidoglycan-degrading or endopeptidase enzymes which can breakdown bacterial cell walls.
- the term “treating” includes prophylaxis as well as the alleviation of established symptoms of an infectious disease or condition.
- the act of "treating" an infection in a subject therefore includes: (1) preventing or delaying the appearance of clinical symptoms of the infectious disease or condition developing in a subject afflicted with the disease or condition; (2) inhibiting the infectious disease or condition (ie arresting, reducing or delaying the development of a bacterial infection or a relapse thereof (in case of a maintenance treatment) or at least one clinical or subclinical symptom thereof); and (3) relieving or attenuating the infectious disease or condition (ie causing regression of the bacterial infection or at least one of its clinical or subclinical symptoms).
- Treatment encompasses single or multiple treatments.
- the phrase "manufacture of a medicament” includes the use of the modified phage directly as a medicament, in combination with other additives, or in any stage of the manufacture of a medicament.
- the term "effective amount” refers to an amount sufficient to effect beneficial or desired clinical results (ie it is a “therapeutically effective amount”).
- a therapeutically effective amount can be administered in one or more administrations.
- a therapeutically effective amount is sufficient for treating an infectious disease or condition, or otherwise to palliate, ameliorate, stabilise, reverse, slow or delay the progression of such a disease or condition.
- a therapeutically effective amount of a modified phage produced in accordance with the method of the first aspect may comprise 10 4 to 10 12 PFU, and more preferably 10 8 to 10 10 PFU.
- the therapeutically effective amount may vary and depend upon a variety of factors including the activity of particular phage(s), the age, body weight, sex and health of the subject, the route and time of administration of the modified phage, and the severity of, for example, the infectious disease or condition, and the type or types of bacteria causative of the infection.
- the modified phage may be used in a combination therapy with a suitable antibacterial agent, in which case, the phage and antibacterial agent (eg an antibiotic) may be administered to the subject consecutively, together or in either order.
- a suitable antibacterial agent eg an antibiotic
- the phage and antibacterial agent may be administered one after another with practically no time interval (ie one is administered effectively immediately after the other) or, otherwise, after an interval of 1 to 5 minutes or more (eg 10 minutes, 30 minutes, 60 minutes, 4 hours or 6 hours).
- the phage and the antibacterial agent are provided in combination for administration in a single pharmaceutical composition.
- Such a pharmaceutical composition may further comprise, for example, a pharmaceutically acceptable carrier, diluent and/or excipient, and may be suitable for, for example, topical administration, intramuscular administration (im), oral administration or intravenous administration (iv).
- a pharmaceutically acceptable carrier diluent and/or excipient
- the phage and the antibacterial agent may each be formulated for administration in a pharmaceutical composition form including a pharmaceutically acceptable carrier, diluent and/or excipient, which may be the same or different.
- the pharmaceutical compositions may be suitable for, for example, topical administration, intramuscular administration (im), oral administration or intravenous administration (iv).
- the present disclosure provides a modified phage produced in accordance with the method of the first aspect.
- the phage may be further propagated using, for example, a sensitive bacterial strain, as required.
- the present disclosure provides a pharmaceutical composition comprising a modified phage produced in accordance with the method of the first aspect, or a further propagated from thereof, optionally in combination with at least one pharmaceutically acceptable additive, carrier, diluent and/or excipient.
- Such a pharmaceutical composition may also comprise one or more additional phage strain(s) (ie in a "phage cocktail") and/or a suitable antibacterial agent (ie for a combination therapy).
- the pharmaceutical composition may optionally comprise other substances such as absorption enhancers including surfactants (eg sodium lauryl sulphate, laureth-9, sodium dodecylsulphate, sodium taurodihydrofusidate and poly oxyethylene ethers), chelating agents (eg EDTA, citric acid and salicylates), and preservatives (eg sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid) and/or suitable binders, lubricants, suspending agents, coating agents and solubilising agents.
- absorption enhancers including surfactants (eg sodium lauryl sulphate, laureth-9, sodium dodecylsulphate, sodium taurodihydrofusidate and poly oxyethylene ethers), chelating agents (eg EDTA, citric acid and salicylates), and preservatives (eg sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid) and/or suitable binders
- binders include starch, gelatin, natural sugars such as glucose, anhydrous lactose, free-flow lactose, beta-lactose, corn sweeteners, natural and synthetic gums, such as acacia, tragacanth or sodium alginate, carboxymethyl cellulose and polyethylene glycol.
- suitable lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
- the at least one pharmaceutically acceptable additive, carrier, diluent and/or excipient may be selected from any of the suitable additives, carriers, diluents and excipients that are well known to those skilled in the art, and which are described in, for example, Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA 1995.
- suitable carriers include lactose, starch, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol and the like.
- suitable diluents include ethanol, glycerol and water.
- suitable excipients may be found in the Handbook of Pharmaceutical Excipients, 2 nd Edition, (1994), Edited by A Wade and PJ Weller.
- compositions may be intended for single daily administration, multiple daily administration, or controlled or sustained release, as needed to achieve the most effective results.
- Examples of pharmaceutical compositions include compositions suitable for delivery by injection, compositions suitable for intravenous administration, compositions suitable for delivery by topical administration, compositions suitable for delivery via a gel, and compositions suitable for pulmonary delivery.
- a suitable composition for topical delivery may comprise a requisite concentration of phage in PBS, in water or in SM buffer (To prepare: NaCl, 5.8 g, 100 mM ; MgSO4•7H2O 2 g, 8 mM ; Tris-Cl (1 M, pH 7.5), 50 ml, 50 mM ; H 2 O to 1 liter).
- the present disclosure provides the use of a modified phage produced in accordance with the method of the first aspect, or a further propagated form thereof, in the manufacture of a medicament for treating an infection in a subject. Methods for manufacturing medicaments are known in the art.
- the present disclosure provides a modified phage, produced in accordance with the method of the first aspect, or a further propagated form thereof, for treating an infection in a subject.
- diseases or conditions suitable for treatment with a modified phage include sinus conditions (eg acute rhinosinusitis and chronic rhinosinusitis), respiratory conditions (eg lung infections, cystic fibrosis), ear conditions (infections of the external ear canal or of the middle ear), diabetic ulcers (eg diabetic foot ulcers), sepsis or a skin infection (eg Staphylococcus skin infections).
- sinus conditions eg acute rhinosinusitis and chronic rhinosinusitis
- respiratory conditions eg lung infections, cystic fibrosis
- ear conditions infections of the external ear canal or of the middle ear
- diabetic ulcers eg diabetic foot ulcers
- sepsis or a skin infection
- Other diseases or conditions are contemplated.
- the modified phage of the present disclosure is typically applied to the treatment of an infectious disease or condition in a human subject.
- the subject may also be selected from, for example, livestock animals (eg cows, horses, pigs, sheep and goats), companion animals (eg dogs and cats) and exotic animals (eg non-human primates, tigers, elephants etc).
- livestock animals eg cows, horses, pigs, sheep and goats
- companion animals eg dogs and cats
- exotic animals eg non-human primates, tigers, elephants etc.
- the method of the seventh aspect may be conducted in, for example, a laboratory setting where, for example, the method may be used to prevent bacterial contamination, and other situations where bacterial infections or contaminations can occur (eg industrial and environmental situations).
- the method of the seventh aspect may be used for decontaminating surfaces and equipment such as food preparation surfaces and equipment, and medical and surgical surfaces and/or equipment etc.
- the bacteria for killing may be present in a planktonic or biofilm form.
- the method of the seventh aspect may also be used for the treatment of a subject.
- the modified phage produced in accordance with the method of the first aspect are capable of infecting and causing lysis of the parent host bacteria.
- the modified phage may show markedly enhanced lytic activity of a level which is at least 1000-fold higher than that of the entry phage.
- Such modified phage may express a novel lysin protein with markedly enhanced lytic activity.
- the present disclosure provides an isolated phage lysin protein (an endolysin) derived from a modified phage produced in accordance with the method of the first aspect.
- the lysin protein may also be formulated into a composition, such as a pharmaceutical composition for use in treating a bacterial infection in a subject (such as those described above), or for killing bacteria in other situations such as environmental contaminations, or for decontaminating surfaces and equipment such as some of those mentioned above including food preparation surfaces and equipment, surgical equipment and air conditioning systems etc.
- Standard techniques and equipment may be used for recombinant DNA technology, DNA sequencing, oligonucleotide synthesis, molecular biology, cell biology and enzymatic reactions, which may be generally performed according to methods known in the art and/or as commercially available, and are as described for example in Sambrook et al.
- aureus ATCC51650 and ATCC25923 were obtained from the American Type Culture Collection (Manassas, VA, United States of America) and used as reference strains. In addition, a total of 15 S. aureus clinical isolates (CIs) were isolated from the sinonasal cavities of chronic sinusitis (CRS) patients. In each case, S. aureus was cultured by an independent diagnostic laboratory and the antibiotic susceptibility determined by disc diffusion on Mueller-Hinton agar per Clinical and Laboratory Standards Institute (CLSI) recommendations (Adelaide Pathology Partners, Mile End, SA, Australia).
- CCSI Clinical and Laboratory Standards Institute
- aureus strains was assessed using the broth microdilution technique as previously described (Wiegand I et al., Nature protocols 3(2):163-175, 2008) and breakpoints defined according to CSLI guidelines. Clinical strains resistant to at least one antibiotic in three or more antibiotic categories were defined as multidrug resistant (MDR).
- MDR multidrug resistant
- Phage sensitivity test The sensitivity of S. aureus isolates (15 clinical isolates and 2 ATCC strains) to phages J-Sa36, Sa83 and Sa87 was determined as previously described (Drilling A et al., Am J Rhinol Allergy 28(1):3-11, 2014). Briefly, 0.5 McFarland Units of S.
- aureus CIs diluted 1:100 in 10 ml Tryptic soy broth (TSB) were grown overnight at 37°C with shaking.200 ⁇ L of overnight broth cultures were then spread onto Columbian blood agar plates evenly (Oxoid). Plates were incubated at 37°C for 1 hour and 5 ⁇ L [10 6 plaque forming units (PFU)] of 3 phages were spotted in triplicates onto the plates and incubated at 37°C overnight.
- Phage buffer solution (SM buffer) alone was spotted in the centre of the plates as negative control. Phage sensitivity was determined according to the protocol described in Zhang G et al., editors.
- Single colonies were transferred to Tryptone Soya Broth (TSB) to generate a culture with a starting concentration of 5 x 10 5 CFU/ml.
- Phage J-Sa36, Sa83 and Sa87 were added to the cultures at multiplicity of infection (MOI) of 0.2 according to predetermined phage titers (described below).
- Antibiotics were added to the cultures at 1 ⁇ 2 MIC (according to the pretest MIC of antibiotics) if required.
- Optical density (OD) readings at 600 nm were recorded at 24 hours to assess the growth of bacteria co-inoculated with phage unless otherwise specified. Uninoculated, fresh media was included as a sterility control.
- Phage titers were determined against S. aureus RN4220 (ATCC) using the double layer spot assay technique. Briefly, 100 ⁇ l of a S. aureus overnight culture was mixed with 4 mL of 0.4% TSA and poured onto a 1.5 % TSA plate. After 20 minutes, serially diluted samples of phage J-Sa36, Sa83 or Sa87 were spotted onto the double layer agar plates in 5 ⁇ l spot volumes in triplicates. After the plates were incubated in a humidified incubator at 37°C overnight, plaques were counted, counts were averaged, and titers of the filtrate were calculated based on the dilution.
- Biofilms were then treated with 8 x10 6 plaque forming units (PFU) of phage J-Sa36, Sa83 or Sa87 and clindamycin added with a final concentration of 1 ⁇ g/ml, 0.5 ⁇ g/ml, 0.2 ⁇ g/ml, 0.1 ⁇ g/ml, or 0.05 ⁇ g/ml, in TSB. Wells were treated for 24 hours at 37°C with gentle shaking.
- PFU plaque forming units
- the AlamarBlue viability assay (Thermo Fisher Scientific, Waltham, MA, United States of America) was used as previously described (Richter K et al., editors. Mind “De GaPP”: in vitro efficacy of deferiprone and gallium ⁇ protoporphyrin against Staphylococcus aureus biofilms. International Forum of Allergy & Rhinology; 2016: Wiley Online Library to determine the anti-biofilm activity of the phage. Fluorescence was measured in a microplate reader (FLUOstar OPTIMA, BMG LABTECH, Offenburg, Germany) and the percent reduction of biofilm after treatment determined relative to untreated controls.
- S. aureus clinical isolate was selected for in vivo experiments that was sensitive to both antibiotics to be used, insensitive to Sa87 phage on planktonic inhibition assays and could be sensitised to phage in the presence of both antibiotics in vitro.
- a fresh culture of CI3 on 1.5% TSA plates was prepared two days before inoculation.
- a single colony was resuspended in 0.9 % saline (ca. 2ml) to turbidity reading 0.5 McFarland Units and then a 1 in 100 dilution in TSB was cultured overnight one day before the in vivo experiment.
- Treatments were administered intranasally twice a day for 21 days, the general wellbeing of the rat (including its appetite, behaviour, and any weight change) being closely monitored.
- the rats were then sacrificed and the sinus mucosal tissue, lungs, heart, liver, kidneys, spleen and brain harvested. Tissue was divided and kept fresh or 10% formalin-fixed, the latter then processed to paraffin wax, and 6 ⁇ m sections cut and stained with haematoxylin and eosin (H&E) for histopathological examination. Formalin fixed tissue was embedded in paraffin and processed to undergo H&E staining and histopathological analysis.
- H&E haematoxylin and eosin
- the fresh sinus mucosa, lungs, heart, liver, kidneys, spleen, and brain were all analysed for phage titers. Faecal samples were collected from all the rats prior to the administration of the first treatment, as well as every day thereafter for phage titers.500 ⁇ l blood samples were collected from the rat tail vein prior to the first treatment and again at 1, 2, 4 and 6 hours following the morning treatment on day 7 and 14 of treatment. This was repeated at 1, 2, 4, 6, 12, 24 and 48 hours following the last treatments on Day 21.
- Phage titers in faeces and organ tissues 1 g of faeces was suspended in 10 mL of SM buffer, centrifuged at 3214 ⁇ g for 10 minutes (Eppendorf 5810 centrifuge, North Ryde, NSW, Australia),filtered (0.22 ⁇ m), and titrated for phage concentration. 1g of rat faeces was collected from every rat at day 0 and daily after the first treatment, and directly placed into 5 mL SM buffer.
- the rat frontal sinus mucosa was dissected and placed directly into 5 mL SM buffer.1cm x 1cm pieces of organ were collected from the brain, lungs, heart, liver, kidney and spleen and were also placed into 5 mL SM buffer. Phage titers and enrichment were performed as previously described (Drilling et al., 2014 supra). Briefly, organ and sinus tissues were ground in 5mL SM buffer using a Qiagen TissueRuptor (Qiagen, Hilden, Germany).
- tissue samples were then centrifuged at 3000 g for 10 minutes, filtered through a 0.22 ⁇ m of syringe filter (Pall Corporation, San Diego, CA, United States of America), and titrated for phage.1g of faeces was suspended in 5 mL of SM buffer, centrifuged at 3214 ⁇ g for 10 minutes (Eppendorf 5810 centrifuge),filtered using a 0.22 ⁇ m filter, and titrated for phage concentration. For phage enrichment, 100 ⁇ L of 0.5 McFarland Units of S. aureus RN4220 diluted 1:100 with 10 ml TSB was grown overnight at 37 ⁇ C with shaking.
- Phage titer in the blood sample 500 ⁇ l of blood was collected from the rat tail vein. Blood tubes were centrifuged at 1000 rpm for 20 minutes at 4°C. The plasma was then harvested and filtered through a 0.22 ⁇ m syringe filter. Phage enrichment was then performed, as above.
- a two-day recovery was given to the rat before treatments begun.
- Treatments were administered intranasally twice a day for 14 days.
- Rats were monitored for weight and respiratory alterations (respiration rate; nasal discharge, hyperaemia or pruritus; and sneezing) during treatment, and, 14 days post-treatment initiation, the rats were humanely sacrificed. Their sinus mucosa was harvested for CFU counting, biofilm quantification, histopathology, and phage enumeration. [00122] Colony-forming unit (CFU) counting of sinus mucosa A fresh (0.2 x 0.2cm) piece of sinus mucosa was harvested and directly placed in 250 ⁇ l 0.9% saline. The mucosa was then homogenised on the highest setting for 30 seconds, or underwent vortex mixing on the highest setting for two minutes.
- CFU Colony-forming unit
- Biofilm biomass quantification on sinus mucosa The quantification of biofilm biomass on sinus mucosa was determined using an established protocol (Singhal D et al., editors. Quantitative analysis of in vivo mucosal bacterial biofilms. International Forum of Allergy & Rhinology; 2012: Wiley Online Library (27).
- the frontal sinus mucosa was harvested and placed into Dulbecco’s Modified Eagle’s Medium (Life Technologies, Carlsbad, CA, United States of America) on ice.
- Dulbecco’s Modified Eagle’s Medium (Life Technologies, Carlsbad, CA, United States of America) on ice.
- One piece of mucosa from each frontal sinus was stained with a LIVE/DEAD® BacLight Bacterial Viability Kit (Life Technologies Australia). The stained mucosa was then examined at 20X magnification using a confocal laser scanning microscope (Zeiss LSM700, Carl Zeiss AG, Oberkochen, Germany).
- the z-stack images (21 slices, interval 1 ⁇ m) were then taken from each sample and, COMSTAT Version 2.1 software was used to measure the biomass of biofilms, the threshold setting being applied so as to minimise background staining (Heydorn A et al., Microbiology 146(10):2395-2407, 2000).
- Post-treatment sinus microbiology analysis A fresh (0.2 x 0.2 cm) piece of mucosa from each rat sinus was harvested and homogenised in 0.9% saline. The supernatant was then harvested and transferred into a new tube without centrifugation. The collected supernatant was serially diluted and plated on blood agar plates in triplicates.
- a further three isolates exhibited resistance to only erythromycin, two isolates exhibited resistance to azithromycin and two exhibited multidrug resistance.
- the isolates were also tested for susceptibility to the three phages, J-Sa36, Sa83 and Sa87.
- J-Sa36 was active in vitro against only 2/17 strains tested (sensitive strains); 2/17 strains were semi-sensitive and 13/17 strains were insensitive (resistant).
- the in vitro activity observed for Sa83 and Sa87 was considerably higher; for Sa83, 11/17 isolates were sensitive or semi-sensitive and 6/17 insensitive and for Sa87, 12/17 isolates were sensitive or semi-sensitive and 5/17 insensitive.
- a synergistic effect was defined as a statistically significant decrease in optical density (OD) that was larger than the combined decrease in OD of antibiotic and phage only controls. None of the combinations of phage with either of the cell wall actives (amoxicillin and vancomycin) showed any significant additive or synergistic effects. However, in contrast, all nine isolates showed synergism with the combination of a PSI antibiotic (erythromycin, clindamycin and azithromycin) and at least one phage. The results for one representative isolate, namely S. aureus CI3, are shown in Figure 1.
- aureus Effects were characterised as resistant (-) if no significant difference in OD was observed compared to untreated control, semi-sensitive ( ⁇ ) if a significant difference was observed but OD remained ⁇ 10% of untreated control, sensitive (+) if growth remained ⁇ 10% of untreated control and synergistic (+) with shading if both sensitive and significantly reduced compared to antibiotic and phage only controls. Dark grey represents synergistic effects against phage resistant strains; light grey represents synergistic effects against semi-sensitive strains. [00131] Dose-dependence of clindamycin in combination with phage J-Sa36 to kill S.
- Incubation with 0.025 ⁇ g/ml (1/8 MIC), 0.05 ⁇ g/ml (1/4 MIC) or 0.1 ⁇ g/ml (1 ⁇ 2 MIC) in combination with J-Sa36 equally reduced OD values compared to positive controls after 24 hours incubation (p ⁇ 0.01).
- aureus biofilms with and without clindamycin Clindamycin alone significantly reduced the viability of preformed ATCC51650 and CI11 biofilms at a concentration of 0.5 ⁇ g/ml (MIC 0.2 ⁇ g/ml) and above, with lower concentrations having no significant effect on biofilm viability.
- Treatment with phages J-Sa36, Sa83 or Sa87 (PFU 8 x 10 6 /ml) alone did not affect CI11 biofilm viability, and J-Sa36 did not affect ATCC51650 biofilm viability.
- aureus phage insensitive and semi-sensitive strains both ATCC51650 and CI11 in liquid culture were incubated with either 1 ⁇ 2 MIC clindamycin or phage J- Sa36 (MOI 0.2) for 3.5 hours. Following this, the alternate treatment was added before continuous incubation with 1 ⁇ 2 MIC clindamycin and phage J-Sa36 for 24 hours. As shown in Figure 4 (A-B), incubation with 1 ⁇ 2 MIC clindamycin or J-Sa36 only did not significantly affect bacterial viability at 24 hours.
- significantly reduced OD600 values were observed for cultures where J-Sa36 was added up to 4 hours post-clindamycin challenge but not when J-Sa36 was added 6 and 24 hours after challenge (see Figure 4 (C-D)).
- Sub-inhibitory (below MIC concentrations) clindamycin enhances phage activity To determine whether clindamycin enhanced phage activity or induced an endogenous prophage, phage titers were determined from cultures of ATCC51650, CI11 and CI8 after incubation for 48 hours with 1 ⁇ 2 MIC clindamycin, phage or both.100 ⁇ l of the resulting culture was then chloroform treated to release phage and the supernatant used to determine phage titers using ATCC51650, CI11 and CI8 as host.
- the initial phage inoculum of 10 4 PFU/ml at 0 hours generated plaques only against ATCC51650 in the presence of clindamycin in the agar overlay, but no plaques were observed for CI11 or CI8. This indicates that a high MOI might be required in addition to clindamycin to facilitate phage lysis in these strains.
- the supernatant of the isolates exposed to 1 ⁇ 2 MIC clindamycin only for ATCC51650, CI11 and CI8 produced no plaques in any of the strains after 48 hours incubation, indicating that no intact prophages that could lyse those isolates were induced by clindamycin treatment.
- J-Sa36 added to ATCC51650 produced no significant increase in phage titer and CI11 produced no plaques, indicating that J-Sa36 cannot infect and replicate in these isolates in the absence of clindamycin. Similar results were observed for phage Sa83; with phage only treatment of CI11 for 48 hours not producing any plaques. In contrast, co-treatment of 1 ⁇ 2 MIC clindamycin and phage led to increased phage titers in all cases.
- ATCC51650 treated with J-Sa36 and 1 ⁇ 2 MIC clindamycin showed a concentration increase from ⁇ 10 4 PFU/ml to 7.73 ⁇ 2.14 ⁇ 10 6 PFU/ml.
- This result indicates that a clindamycin-mediated phage infection is capable of producing new phage particles, not simply leading to host cell death.
- the same result was observed for CI11 treated with J-Sa36 and 1 ⁇ 2 MIC clindamycin (1.9 ⁇ 1.3 ⁇ 10 9 PFU/ml), and Sa83 and 1 ⁇ 2 MIC clindamycin (6.4 ⁇ 2.6 ⁇ 10 7 PFU/ml).
- aureus CFU counts/ml compared to rats treated with 0.5 x 10 10 PFU/ml Sa87, 1 ⁇ 2 MIC clindamycin or 1 ⁇ 2 MIC azithromycin (p > 0.05). Sensitivity testing indicated similar sensitivity to the antibiotics and insensitivity to Sa87 for the post- and pre-treatment S. aureus isolates. In contrast, no S. aureus were cultured in rats treated with 0.5 x 10 10 PFU/ml Sa87 in combination with 1 ⁇ 2 MIC clindamycin or azithromycin and were significantly lower than control saline-treated rats or rats treated with Sa87 or 1 ⁇ 2 MIC clindamycin or azithromycin (p 0.0086) (see Figure 5A). However, bacterial colonies that were not S.
- aureus were grown from the nasal mucosa of those rats (CFU counts of ⁇ 500 CFU/mL).
- MALDI-TOF analysis identified those bacteria to be E. coli and E. faecalis.
- Biofilm biomass quantitation showed similar biomass quantities in controls, Sa87 and 1 ⁇ 2 MIC clindamycin treated rats and a significant increase in biomass in 1 ⁇ 2 MIC azithromycin treated rats as compared to control.
- histopathology of the maxilloturbinates by a pathologist showed normal ciliated pseudostratified respiratory epithelium with no evidence of inflammation or glandular hyperplasia in rats treated with Sa87 in combination with 1 ⁇ 2 MIC clindamycin or azithromycin.
- rats treated with Sa87, 1 ⁇ 2 MIC clindamycin, 1 ⁇ 2 MIC azithromycin or saline only there was evidence of cilial denudation and surface epithelial erosion, with desquamated necrotic luminal cellular debris admixed with neutrophils.
- Example 2 [00137] The study described in this example aimed to provide further evidence that sub-inhibitory concentrations of PSI antibiotics can sensitise phage non-sensitive S. aureus to phage infection, and additionally, provide some characterisation of the progeny phage (exit phage).
- Materials and Methods [00138] Bacterial strains and growth conditions S. aureus strains frozen stocks were thawed and streaked on 1.5% trypticase soy agar (TSA) (Oxoid) plates at 37°C overnight.
- TSA trypticase soy agar
- E4643 E. coli expression strain was an E. coli made in Shearwin Laboratory from E4640+ (Shearwin K., School of Biological Sciences, University of Sydney, Sydney, SA, Australia).
- Phages and phage titer determination Two strictly lytic S. aureus phages (APTC-SA-2 and APTC-SA-12; Sydney Phage Therapy Centre, Sydney, SA, Australia) were used for all experiments. The phages were identified as being of the genus Kayvirus, subfamily Twortvirinae, family Herelleviridae. Phage titers were determined against S. aureus RN4220 (ATCC) using the double layer spot assay (DLSA).
- Phage sensitivity test Sensitivity tests of S. aureus clinical isolates was performed as described previously (Drilling et al., 2014 supra). Briefly, 200 ⁇ l of an overnight S.
- aureus culture was spread onto Columbian blood agar plates (Oxoid) and then the plates were incubated at 37°C for 1 hour.5 ⁇ l diluted phage (10 6 PFU/ml) were spotted onto the plates in triplicates. Phage buffer solution (SM buffer and TSB) was spotted in the centre of the plates as a negative control. Phage sensitivity was determined as previously described after overnight incubation at 37°C (see Zhang G et al., 2018 supra).
- Results were interpreted as follows: Sensitive: ⁇ 0.2 ⁇ g/mL; Intermediate: 0.4 ⁇ g/ml; Resistant: ⁇ 0.6 ⁇ g/mL.
- the S. aureus strains sensitive to clindamycin were selected for further tests. The MIC was performed three times.
- Phage and clindamycin combination treatment A phage and clindamycin synergy assay was performed using 96 well plates. In brief, selected S. aureus strains (phage non-sensitive) were grown on 1.5 % TSA at 37°C overnight. A single colony was transferred to TSB to generate a culture with a starting concentration of 5 x 10 5 CFU/ml.
- One-step growth curve was performed as detailed previously (Chang Y et al., Viruses 7(10):5225- 5242, 2015). Briefly, 100 ⁇ L phages (1 ⁇ 10 8 PFU/mL) were mixed with 1 mL S. aureus (1.5 x 10 8 CFU/mL) culture at a MOI of 0.1 in 8.9 mL TSB and incubated at 37 °C for 5 min. The mixture was then centrifuged, and the pellets were resuspended in 9.9 mL fresh TSB. The resuspended pellets were incubated at 37 °C with shaking at 180 rpm.100 ⁇ L mixture was taken every 30 min.
- BIMs bacteriophage-insensitive mutants
- E. coli expressing phage proteins and PHEARLESS assay A system, termed PHEARLESS (phage-based expression, amplification, and release of lytic enzyme species), was used to express phage proteins of interest in E. coli comprising three components engineered into the E. coli expression strain (E4643), namely (1) the integrated cumate inducible 186tum induction module, (2) the engineered 186 ⁇ tum prophage genome and (3) the protein expression plasmid.
- the E.coli containing the target protein expression plasmids were streaked out on LB agar plates with spectinomycin (50 ⁇ g/mL; Sigma Aldrich, Bayswater, VIC, Australia) and the S. aureus strains C319, C244, C330, C43, C259 and ATCC29923, were streaked out on LB agar plates. The plates were incubated at 37 °C degrees overnight. A single colony of the E. coli expression strain was picked to grow in LB broth with spectinomycin (50 ⁇ g/mL) overnight to generate a fresh bacterial culture. Similarly, a single colony of each of the S. aureus strains was picked to grow in LB broth overnight.
- Phage sensitivity test A total of 60 S. aureus clinical isolates were tested for their phage sensitivity in order to select those that were insensitive to both lytic APTC-SA-2 and APTC-SA-12 S. aureus phage.
- aureus strains (C43, C330, C285 and C319) were selected to be treated with the APTC-SA-2 and APTC-SA-12 phage combined with 1 ⁇ 2 MIC clindamycin.
- the combination treatment could kill the bacteria after 24 hours and was significantly more effective than control (ie bacteria with TSB), or treatment with 1 ⁇ 2 MIC clindamycin and phage only.
- the growth of S. aureus bacteria was similar among control, 1 ⁇ 2 MIC clindamycin treated, and phage only treated groups (see Figure 6A-B, D-E).
- ATCC 25923 was sensitive to both phage types, and phage in combination with 1 ⁇ 2 MIC clindamycin were equally effective at killing this strain compared to no-treatment control and to 1 ⁇ 2 MIC clindamycin ( Figure 6C and F).
- Exit phage bactericidal activity To evaluate whether the progeny phage particles (exit phage), produced after sensitisation of non- sensitive S.
- aureus strains with 1 ⁇ 2 MIC clindamycin and adding the entry phage were effective at killing their own parent strain, exit phage particles were purified for both APTC-SA-2 or APTC-SA-12 entry phage after they went through an infection cycle of two representative non-sensitive S. aureus strains.
- TSB positive control
- entry phage treatment APTC-SA-2 or APTC-SA-12
- PHEARLESS assay The PHEARLESS assay described above was conducted to investigate the lytic activity of the exit phage. In particular, the assay was conducted to investigate and compare the lytic activity of the lysin protein of the entry phage (LysK) with that of the exit phage (denoted mLysK). Briefly, exit phage mLysK expression constructs were prepared from APTC-SA-2-C330 and from APTC-SA-2-C319 and an entry phage LysK expression construct was prepared from APTC-SA-2. All expression constructs were transformed into the PHEARLESS system and tested against the S.
- aureus phage non-sensitive strains C319, C285, C330 and C43 and also against the phage sensitive ATCC25923 to evaluate their ability to facilitate bacterial lysis.
- the entry phage LysK only showed weak lytic activity against ATCC25923 as a zone of clearing was observed at the highest dosage only, whilst all other strains remained unaffected by the entry phage LysK.
- the expressed exit phage mLysK from APTC-SA-2-C330 (298) and from APTC-SA-12-C319 (294) showed lytic activity against all of the tested strains in a dose-dependent way (zone of clearing appearance clear to blurred from highest dosage to lowest dosage).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
A method of producing modified bacteriophage ("phage") that are capable of infecting and causing lysis of a parent host bacteria that is insensitive to the unmodified phage is disclosed. The method comprises: treating a host bacteria insensitive to a selected phage strain with a suitable amount of the said phage strain and at least one antibacterial agent comprising protein synthesis inhibitory activity, and culturing the bacteria for a period and under conditions suitable for the phage to infect the bacteria and replicate to generate progeny phage; and recovering and expanding progeny phage which are phage with a modified capability to infect and cause lysis of said host bacteria. Methods of treatment involving the use of the modified phage, as well as pharmaceutical compositions comprising same are also disclosed.
Description
METHOD OF PRODUCTION OF MODIFIED PHAGE AND METHOD OF TREATMENT USING SAME TECHNICAL FIELD [0001] The present disclosure relates to the field of bacteriophage therapy, particularly in the circumstance of the treatment of a drug-resistant bacteria which is also bacteriophage non-sensitive (insensitive). Among other things, the present disclosure relates to a method of producing modified bacteriophage that are capable of infecting and causing lysis of a parent host bacteria that is insensitive to the unmodified bacteriophage. PRIORITY DOCUMENT [0002] The present application claims priority from Australian Provisional Patent Application No. 2022901885 titled "METHOD OF PRODUCTION AND TREATMENT" and filed on 5 July 2022, the content of which is hereby incorporated by reference in its entirety. BACKGROUND [0002] Many human and animal illnesses are caused by infection with bacteria. The economic and social toll of bacterial disease is enormous. However, while the development of antibiotics has largely mitigated the effects of diseases caused by bacteria, the development of bacteria that are resistant to the action of antibiotics has ushered in an undesirable era where the suite of antibiotics for use has become more limited and made some bacterial infections untreatable as they have acquired resistance to the known antibiotics. [0003] Indeed, the misuse and abuse of antibiotics, either among humans or among animals, has boosted the fast expansion of drug-resistant microorganisms. Current studies suggest that the mechanisms of bacterial antibiotic resistance include either a reduction in the affinity of the antibiotic agent to bind to its bacterial target protein or a reduction in the bacterial intracellular drug concentration. The former is primarily caused by the emergence of mutation(s) in the genes encoding the target protein of the antibiotic, while the latter is mainly achieved through alterations in the plasma membrane permeability, expression of degradation/modification enzymes, or overexpression of efflux pumps. [0004] Additionally, bacteria can increase their tolerance and resistance to antibiotics through the formation of a biofilm, which then acts as a natural barrier to prevent the absorption of antibacterial drugs such as antibiotics. The biofilm drug-resistance mechanism is different from that of individual
bacteria and, compared with planktonic bacteria, this drug-resistance mechanism can increase the bacterial antibiotic tolerance 10- to 1000-fold, and is one of the main causes of current bacterial drug resistance. The extracellular polymeric substance (EPS) secreted by bacteria, one of the main components of a biofilm, forms a dense and negatively charged natural barrier, which prevents the penetration of antibiotics and other antibacterial drugs into the membrane, thus reducing the concentration of drugs inside the membrane. Additionally, the lack of enough nutrients inside of the biofilm will inhibit the bacterial metabolic activity, and subsequently promote bacteria to enter a dormant state, making them more resistant to the drug during the reproduction period as many antibiotics rely on proliferation of the bacteria for effectiveness. [0005] Moreover, the mechanisms for the resistance of bacteria to antibiotics and formation of biofilms are complex, and there are synergistic effects among the various mechanisms. Thus, drug- resistant bacteria, especially the so-called "superbugs" (eg methicillin-resistant Staphylococcus aureus (MRSA)), have rapidly spread to every corner of the world, leading to longer hospital stays, higher medical costs and mortality rates. Indeed, antibiotic-resistant bacteria now represent one of the greatest threats to global public health. Therefore, identifying and developing new ways to treat bacteria, including drug-resistant bacteria, quickly and effectively has become critical. [0006] Bacteriophage ("phage") can invade their bacteria host to disrupt the host metabolism and, eventually, cause lysis and killing of the host cell. Phage were first applied to anti-bacterial infection treatments in clinics over 100 years ago, and they were utilised specifically to kill and target bacterial hosts causing infection. Due to the discovery and widespread use of antibiotic agents, the use of phage has diminished. However, due to the ongoing problem of drug-resistant bacteria (and especially, the multidrug-resistant (MDR) bacteria), phage therapy has now returned to the spotlight. Further, it is now more fully appreciated that phage possess unique advantages that may mean that phage targeting specific pathogenic bacteria can be isolated to meet clinical needs more quickly than the development of novel antibacterial drugs. Phage are also very abundant in nature, lack cross-resistance with antibiotics, and are highly specific (compared to antibiotics). Moreover, phage can also be effective in disrupting bacterial biofilms, and offer enormous potential to serve as the basis of therapies providing an effective and sustainable solution for the treatment of bacteria, including treatment for superbugs and refractory MDR bacterial infections. [0007] Notwithstanding the renewed interest in phage and phage therapy, the utility of phage in the clinic has been limited. Part of the reason for the lack of adoption of phage therapy is the narrow antibacterial spectrum of many phage. Further, many clinical isolates are resistant to known phage. In such conditions, a patient may have a considerable waiting period until a suitable phage is available for treating their specific bacterial infection and/or there are no phage suitable to infect a particular resistant bacterial infection. For this reason, strategies for phage therapy need to be identified which
address the problem of the occurrence or development of phage insensitive bacteria. To this end, the Applicants looked to determine whether phage insensitive bacteria could be "re-sensitised" to phage and thereby be treatable by phage therapy. SUMMARY [0008] According to a first aspect, the present disclosure provides a method of producing a modified phage, said method comprising the steps of: (i) treating a host bacteria insensitive to a selected phage strain (ie a phage non-sensitive, or phage insensitive, or phage resistant bacteria) with a suitable amount of the said phage strain and at least one antibacterial agent comprising protein synthesis inhibitor activity, and culturing the bacteria for a period and under conditions suitable for the phage to infect the bacteria and replicate to generate progeny phage; and (ii) recovering and expanding progeny phage which are phage with a modified capability to infect and cause lysis of said host bacteria. [0009] In some embodiments, the host bacteria is a sample of a bacteria causative of an infection being suffered by a subject, and the phage is a phage selected from a "phage bank" and is one that is normally regarded as infectious for the host bacteria if not for the circumstance that the bacteria has become insensitive to the phage (ie is phage non-sensitive). The progeny phage have a modified capability to infect and cause lysis of said host bacteria, and may therefore be useful in treating the infection in the subject. [0010] In a second aspect, the present disclosure provides a method of treating a bacterial infection in a subject, said method comprising the steps of: 1. obtaining a sample of a bacteria causative of an infection in said subject, 2. treating the bacteria with a suitable amount of a selected phage strain to which the bacteria is insensitive (ie the bacteria is phage non-sensitive) and at least one antibacterial agent comprising protein synthesis inhibitory activity, and culturing the bacteria for a period and under conditions suitable for the phage to infect the bacteria and replicate to generate progeny phage; 3. recovering and expanding progeny phage which are phage with a modified capability to infect and cause lysis of said host bacteria; and 4. administering to the subject an effective amount of the progeny phage, or a further propagated form thereof, to treat the infection. [0011] In a third aspect, the present disclosure provides a modified phage produced in accordance with the method of the first aspect, or a further propagated form thereof.
[0012] In a fourth aspect, the present disclosure provides a pharmaceutical composition comprising a modified phage produced in accordance with the method of the first aspect, or a further propagated from thereof, optionally in combination with at least one pharmaceutically acceptable additive, carrier, diluent and/or excipient. [0013] In a fifth aspect, the present disclosure provides the use of a modified phage produced in accordance with the method of the first aspect, or a further propagated form thereof, in the manufacture of a medicament for treating an infection in a subject. [0014] In a sixth aspect, the present disclosure provides a modified phage, produced in accordance with the method of the first aspect, or a further propagated form thereof, for treating an infection in a subject. [0015] In a seventh aspect, the present disclosure provides a method of killing bacteria, said method comprising contacting the bacteria with a modified phage produced in accordance with the method of the first aspect or a further propagated form thereof. [0016] In an eighth aspect, the present disclosure provides an isolated phage lysin protein (an endolysin) derived from a modified phage produced in accordance with the method of the first aspect. BRIEF DESCRIPTION OF FIGURES [0017] Figure 1 provides the results of experimentation to determine any synergy between phage and various antibiotic agents on bacterial viability. Protein synthesis inhibitors (PSI) erythromycin (E), clindamycin (C) and azithromycin (Az), but not cell wall actives amoxicillin (A) and vancomycin (V), were found to have synergistic effects with phage J-Sa36 (Sa36), Sa83 and Sa87 to reduce or eradicate a clinical isolate of S. aureus (CI3). OD600 values, representing bacterial viability, were measured after 24 hours in the absence (TSB) or presence of ½ MIC (minimum inhibitory concentration) antibiotics alone, phage alone (MOI = 0.2), or the combination of ½ MIC antibiotics and phage (MOI = 0.2). Significant reductions were observed, compared to treatment with phage or antibiotic alone, for all combinations of phage and PSIs. n=3. Bars represent standard error of the mean (SEM). ns=not significant, ****, p < 0.0001; [0018] Figure 2 provides the results of experiments to assess whether enhanced bacterial killing by the combination of clindamycin and phage was dose dependent. The results show that low (1/8th MIC) doses of clindamycin in combination with J-Sa36 (Sa36) were effective against S. aureus (ATCC51650 and CI11). OD 600 values represent bacterial growth of (A) ATCC51650 and (B) CI11 after 24 hours exposure to 105 PFU/ml J-Sa36 (MOI=0.2) and varying clindamycin concentrations
(0.005 μg/ml -1/32 MIC to 0.1μg/ml-½ MIC) or control (TSB). ns=not significant, ****, p < 0.0001, one-way ANOVA with Tukey's multiple comparisons test. n=3. Bars represent standard error of the mean (SEM). Black bars represent S. aureus ATCC51650 and CI11 treated with medium (TSB), J- Sa36 (Sa36) or clindamycin (½ MIC or 0.1μg/ml) as control. Grey bars represent S. aureus ATCC51650 and CI11 treated with J-Sa36 combined with different concentrations of clindamycin; [0019] Figure 3 provides results showing that the phage J-Sa36, Sa83 or Sa87 combined with clindamycin reduces the viability of ATCC51650 and CI11 biofilms. In particular, the reduction of biofilm viability of S. aureus (A) ATCC51650 and (B) CI11 was measured by Alamar Blue viability assay, and the measurements normalised and compared to untreated control (0 μg/ml). The concentrations of clindamycin ranged from 1, 0.5, 0.2, 0.1, 0.05 and 0 μg/ml. ns=not significant, *, p < 0.05, Significance was determined by one-way ANOVA with Dunnett's multiple comparisons test in comparison with phage only controls. n=3. Bars represent standard error of the mean (SEM); [0020] Figure 4 provides results which show the time dependent effects on phage-antibiotic synergy: (A, B) S. aureus ATCC51650 or CI11 were grown in the absence (control) or presence of J- Sa36 (Sa36; MOI 0.2) or ½ MIC clindamycin for 3.5 hours, followed by the addition of ½ MIC clindamycin (Sa36+ ½ MIC clindamycin added at 3.5 hrs) or phage J-Sa36 (½ MIC clindamycin + J- Sa36 added at 3.5 hrs) with OD600 recorded at 3.5 (black bars) and 24 hours (grey bars); (C, D) ATCC51650 and CI11 respectively were pre-treated for different times with either ½ MIC clindamycin (black bar) or TSB only (grey) before J-Sa36 (MOI 0.2) was added at 1, 2, 3, 3.5, 4, 6 and 24 hrs. OD600 was recorded 24 hours later. n=3.ns=not significant, ****, p < 0.0001; ***, p < 0.001; **, p < 0.01; *, p < 0.05, mixed ANOVA with Tukey’s multiple comparisons test. Bars represent standard error of the mean (SEM); [0021] Figure 5 provides the results of in vivo efficacy tests of phage and antibiotic combinations. Colony Forming Unit (CFU) counts (CFU/ml) (A) and biofilm biomass (μm3/μm2) (B) of a fresh piece of rat sinonasal mucosa from rats treated with 0.5 x 1010 PFU/ml Sa87 in combination with ½ MIC clindamycin [Sa87 + C], 0.5 x 1010 PFU/ml Sa87 in combination with ½ MIC azithromycin [Sa87 + Az], 0.5 x 1010 PFU/ml Sa87 [Sa87], ½ MIC clindamycin [C], ½ MIC azithromycin [Az], saline [Saline]. Experiments were performed with three replicates for each rat, averaged and each rat represented by 1 dot. ****, p < 0.0001; **, p < 0.01; *, p < 0.05, One-way ANOVA with Dunnett's post hoc test. Error bars represent standard error of the mean (SEM). [0022] Figure 6 provides graphical results showing that the combination of S. aureus phage and ½ MIC clindamycin kills non-sensitive S. aureus strains: (A) S. aureus C43 treated with APTC-SA-2 and ½ MIC clindamycin; (B) S. aureus C330 treated with APTC-SA-2 and ½ MIC clindamycin; (C) S. aureus ATCC25923 treated with APTC-SA-2 and ½ MIC clindamycin; (D) S. aureus C285 treated
with APTC-SA-12 and ½ MIC clindamycin; (E) S. aureus C319 treated with APTC-SA-12 and ½ MIC clindamycin; and (F) S. aureus ATCC25923 treated with APTC-SA-12 and ½ MIC clindamycin. Significance was determined compared to untreated control. Data expressed as mean ^ SEM for three independent experiments. ****, p<0.0001; ns, no significant. C=clindamycin; [0023] Figure 7 provides the results of bactericidal activity tests performed on exit phage. The exit phage's bactericidal activity was tested in its own host, S. aureus C43 (A), C330 (B), C285 (C) and C319 (D), each time treated with TB (control), the entry phages APTC-SA-2 (A, B) and APTC-SA-12 (C, D) (MOI=1) or exit phages APTC-SA-2-C43 (A), APTC-SA-2-C330 (B), APTC-SA-12-C285 (C) and APTC-SA-12-C319 (D). Significance was determined compared to untreated control. Data expressed as mean ^ SEM for three independent experiments. **, p<0.01; ****, p<0.0001; ns, no significant; [0024] Figure 8 shows graphical results of tests for the exit phage specificity and lytic activity. S. aureus clinical isolates C43 (A, E), C330 (B, F), C285 (C, G) and C319 (D, H) were treated with TSB (control), entry phages APTC-SA-2 (A, B) or APTC-SA-12 (C, D), or exit phages APTC-SA-2-C43 (A, E), APTC-SA-2-C330 (B, F), APTC-SA-12-C285 (C, G) or APTC-SA-12-C319 (D, H) at MOI=1 (A-D) or at MOI 0.2-0.001 (E-H). Significance was determined compared to untreated control. Data expressed as mean ^ SEM for three independent experiments. ****, p<0.0001; ns, not significant. ATCC=ATCC25923; [0025] Figure 9 provides characterising (stability and growth) results for entry phage and exit phage: (A) Entry phage APTC-SA-2 and APTC-SA-12 and exit phage APTC-SA-2-C43, APTC-SA- 2-C330, APTC-SA-12-C285 and APTC-SA-12-C319 temperature stability was tested between 4 to 80o C; (B) Entry phage APTC-SA-2 and APTC-SA-12 and exit phage APTC-SA-2-C43, APTC-SA-2- C330, APTC-SA-12-C285 and APTC-SA-12-C319 pH stability was tested between pH 3 to 12; (C) Entry phage APTC-SA-2 and APTC-SA-12 and exit phage APTC-SA-2-C43, APTC-SA-2-C330, APTC-SA-12-C285 and APTC-SA-12-C319 one-step growth curve were performed. Data expressed as mean ^ SEM for three independent experiments; and [0026] Figure 10 shows the results of a representative PHEARLESS Assay to determine the lytic activity of exit phage produced in accordance with the method of the disclosure. The expressed lysin protein (LysK) of the exit phage (APTC-SA-2-C330 ("294") and APTC-SA-2-C319 ("298")) was applied to S. aureus strains (C319) at the various concentrations indicated in the figure. "302" is a negative control (expressing no phage lysin). Arrow=lysis plaque.
DETAILED DESCRIPTION [0027] As described in the examples hereinafter, the Applicants found that treatment of phage non- sensitive S. aureus with lytic phage in combination with a sub-inhibitory concentration (MIC) of erythromycin, clindamycin and azithromycin, can significantly reduce the growth of the bacteria. Characterisation of the phage isolated after the treatment ("exit phage") then, surprisingly, revealed that the phage were able to re-infect their "parent" bacterial host without the need (or "help") of the antibiotic, and moreover, with up to a 1000-fold higher level of lytic activity as compared to that of the "entry phage" (ie the initial phage used). In other words, the dosage of exit phage to have significant antibacterial effects against the parent bacterial host was less than 1000th the dosage of the entry phage and the entry phage could only infect the parent bacteria in the presence of protein synthesis inhibitor (PSI) antibiotics whilst the exit phage could infect the parent bacterial strains also in the absence of PSI antibiotics. The stability (ie temperature and pH stability) of the exit phage and their growth curve were, however, substantially unchanged and, in particular, showed no significant difference when compared with the corresponding entry phage. In addition, it was found that the burst size of the exit phage was higher than the entry phage (ie the burst size (calculated at 30min) for entry phage APTC- SA-2 was 30 PFUs/infected cell; while for exit phage APTC-SA-2-43, the burst size was 40 PFUs/infected cell, and for exit phage APTC-SA-2-330, 42 PFUs/infected cell. Similarly, for entry phage APTC-SA-12, the burst size was 14 PFUs/infected cell, in comparison to burst sizes of 33 and 38 PFUs/infected cell, respectively, for the exit phage APTC-SA-12-C285 and exit phage APTC-SA- 12-319). Moreover, from a bacteriophage insensitive mutant (BIM) frequency test, it was found that exit phage showed a significantly lower BIM frequency compared to entry phage. As such, the Applicants have identified a novel method for the production of a modified phage, derived from a phage for which a host bacterial strain is or has become insensitive (ie the bacteria is phage non- sensitive), which is capable of infecting the host bacteria strain and, preferably, also shows an enhanced level of lytic activity with a reduction in dosage required to achieve bacterial eradication, an increase in the burst size of the exit phage, and/or achieves a reduction in the frequency of emergence of bacteriophage insensitive mutants (BIM) when bacteria are treated with the exit phage compared to when they are treated with the parent entry phage (in the presence of sub-inhibitory PSI antibiotics). [0028] Thus, in a first aspect, the present disclosure provides a method of producing a modified phage, said method comprising the steps of: (i) treating a host bacteria insensitive to a selected phage strain (ie a phage non-sensitive, or phage insensitive, or phage resistant bacteria) with a suitable amount of the said phage strain and at least one antibacterial agent comprising protein synthesis inhibitor activity, and culturing the bacteria for a period and under conditions suitable for the phage to infect the bacteria and replicate to generate progeny phage; and
(ii) recovering and expanding progeny phage which are phage with a modified capability to infect and cause lysis of said host bacteria. [0029] In this first aspect, the present disclosure provides a method of producing phage with improved lytic activity against a phage insensitive bacteria, by exposing the insensitive host bacterium to a selected infecting phage and an agent having protein synthesis inhibitory activity, and producing a phage with improved lytic activity against the insensitive bacteria. [0030] The host bacteria used in step (i) may be any phage insensitive bacteria strain, but preferably, will be a phage insensitive bacteria strain of medical and/or veterinary significance. [0031] In some embodiments, the host bacteria is selected from the group consisting of Staphylococcus species, Streptococcus species, Enterococcus species, Corynebacterium species, Bacteroides species, Bacillus species, Yersinia species, Legionella species, Francisella species, Salmonella species, Gordonia species, Mycobacterium species, Acinetobacter species, Clostridium species, Pseudomonas species, and Enterobacteriaceae species. [0032] In some embodiments, the host bacteria is selected from the group consisting of S. aureus, S. epidermidis, S. lugdunensis, Acinetobacter baumannii, Clostridium difficile, and Pseudomonas aeruginosa. [0033] In some embodiments, the host bacteria is a drug-resistant bacteria, such as an antibiotic- resistant bacteria, and especially a multidrug-resistant (MDR) bacteria or superbug, such as methicillin-resistant Staphylococcus aureus (MRSA). [0034] In some embodiments, the host bacteria is a bacteria having a characteristic of the ability to form a biofilm. [0035] In some particular embodiments, the host bacteria is an S. aureus bacteria, or may otherwise be of a species such as Acinetobacter baumannii (which can cause life-threatening infections in the blood, lungs, urinary tract and in wounds), Clostridium difficile (which can cause life-threatening infections and damage to the intestinal mucosa), Pseudomonas aeruginosa (which is a common cause of chronic airway infections in cystic fibrosis patients, and which can cause serious infections in the ear, skin, blood and parts of the body following surgery), and Enterobacteriaceae species (such as E.coli, E. faecium such as vancomycin-resistant E. faecium, and Klebsiella spp. such as K. pneumoniae). [0036] In some further particular embodiments, the host bacteria is selected from the group consisting of multidrug resistant (MDR) strains of bacteria. In addition to MDR strains of S. aureus,
examples of MDR strains of A. baumannii, E. coli, Klebsiella spp. and P. aeruginosa are also particularly well known and widespread. [0037] The host bacteria used in step (i) may, preferably, be a clinical isolate and, in particular, a clinical isolate from a subject requiring treatment for a bacterial infection; that is, the host bacteria is a sample of the bacteria causative of an infection being suffered by a subject. In some embodiments, the host bacteria is a clinical isolate from a bacterial infection characterised by the presence of a bacterial biofilm. [0038] In some embodiments, the bacteria are gram-negative bacteria, while in some other embodiments, the bacteria are gram-positive bacteria. [0039] Some particular examples of suitable host bacteria that may be used in step (i) include bacteria from the following species: Bacillus (eg Bacillus anthracis), Brochothrix, Corynebacterium, Enterococcus, Fingoldia (eg Fingoldia magna), Francisella (eg Francisella tularensis) Geobacillus, Gordonia, Lactobacillus, Leuconostoc, Lactococcus, Legionella, Listeria, Microcystis, Mycobacterium (eg Mycobacterium abscessus, Mycobacterium tuberculosis), Nocardia, Pediococcus, Propionibacterium, Rhodococcus, Staphylococcus (eg Staphylococcus aureus; Staphylococcus epidermidis, Staphylococcus lugdunensis) Streptococcus, Aeromonas, Azospirillum, Aggregatibacter, Bacteroides, Burkholderia, Brucella, Campylobacter, Candidatus, Caulobacter, Clavibacter, Cronobacter, Delftia, Escherichia, Erwinia, Flavobacterium, Haemophilus, Halomonas, Iodobacteria, Klebsiella, Kluyvera, Mannheimia, Morganella, Pantoea, Alphaproteobacteria, Planktothrix, Pseudoalteromonas, Pseudomonas (eg Pseudomonas aeruginosa), Pasteurella, Salmonella, Shigella, Sinorhizobium, Sodalis, Synechococcus, Thalassomonas, Thermus, Vibrio, Xanthomonas, Xylella and Yersinia. Other bacterial species are, however, also contemplated. Phage capable of infecting the abovementioned bacteria are known to those skilled in the art. [0040] In some embodiments, the bacteria are selected from bacteria of the following genus:
Citrobacter
Cronobacter
[0041] The host bacteria is treated in step (i) with a suitable amount of a phage that would normally be regarded as infectious for the bacteria if not for the circumstance that the particular bacterial strain concerned has become insensitive to the phage. For example, where the host bacteria is S. aureus, the phage may be a phage that is normally infectious for S. aureus. [0042] Examples of Staphylococcus phage include phage from the Myoviridae, Siphoviridae, Podoviridae, Picovirinae, Spounavirinae, and Twortlikevirus families. [0043] Examples of Staphylococcus phage include Staphylococcus phage SA1, Staphylococcus phage phi13, Staphylococcus phage phi2958PVL, Staphylococcus phage phiETA2, Staphylococcus
phage phiETA3, Staphylococcus phage phiMR11, Staphylococcus phage phiMR25, Staphylococcus phage phiNM, Staphylococcus phage phiNM3, Staphylococcus phage phiPVL108, Staphylococcus phage phiPVL-CN125, Staphylococcus phage phiSauS-IPLA35, Staphylococcus phage phiSauS- IPLA88, Staphylococcus phage phiSLT, Staphylococcus phage PVL, Staphylococcus phage SAP-2, Staphylococcus phage SAP-26, Staphylococcus phage tp310, Staphylococcus phage tp310-2, Staphylococcus phage tp310-3, Staphylococcus phage Twort, Staphylococcus phage phi11, Staphylococcus phage 187, Staphylococcus phage 2638A, Staphylococcus phage 37, Staphylococcus phage 3A, Staphylococcus phage 42E, Staphylococcus phage 44AHJD, Staphylococcus phage 29, Staphylococcus phage 52A, Staphylococcus phage 53, Staphylococcus phage 69, Staphylococcus phage 71, Staphylococcus phage 85, Staphylococcus phage 88, Staphylococcus phage 92, Staphylococcus phage 96, Staphylococcus phage X2, Staphylococcus phage 55, Staphylococcus phage 66, Staphylococcus phage 77, Staphylococcus phage 80alpha, Staphylococcus phage CNPH82, Staphylococcus phage K, Staphylococcus phage P954, Staphylococcus phage PH15, Staphylococcus phage phi 12, Staphylococcus phage EW, Staphylococcus phage TEM126, Staphylococcus phage S13', Staphylococcus prophage phiPV83, Staphylococcus phage phiETA, Staphylococcus phage S24-1, and Staphylococcus phage G1. [0044] Where the host bacteria is an Enterococcus bacterial species, then the phage used in step (i) may be selected from examples of Enterococcus phage such as those from the Siphoviridae and Myoviridae families. [0045] Particular examples of Enterococcus phage include Enterococcus phage EFAP-1, Enterococcus phage phiEf11, Enterococcus phage phiEF24C, Enterococcus phage phiFL1A, Enterococcus phage phiFL2A, Enterococcus phage phiFL3A, Enterococcus phage phiFL4A, and Enterococcus phage SAP6. [0046] Where the host bacteria is an Corynebacterium, then the phage used in step (i) may be selected from examples of Corynebacterium phage such as those of the Siphoviridae family. [0047] Particular examples of Corynebacterium phage include Corynebacterium phage BFK20 and Corynebacterium phage P1201. [0048] Where the host bacteria is a Pseudomonas, then the phage used in step (i) may be selected from examples of Pseudomonas phage including phage of the Podoviridae, Autographivirinae, Siphoviridae, Podoviridae, Myoviridae and Cystoviridae families. [0049] Particular examples of Pseudomonas phage include Pseudomonas phage H105/1, Pseudomonas phage LKA1, Pseudomonas phage B3, Pseudomonas phage D3, Pseudomonas phage
F10, Pseudomonas phage F116, Pseudomonas phage F8, Pseudomonas phage gh-1, Pseudomonas phage LBL3, Pseudomonas phage LKD16, Pseudomonas phage LMA2, Pseudomonas phage LUZ19, Pseudomonas phage PA11, Pseudomonas phage PAJU2, Pseudomonas phage PaP3, Pseudomonas phage PB1, Pseudomonas phage phi13 (S-segment), Pseudomonas phage phi15, Pseudomonas phage phi-2, Pseudomonas phage phi2954 (S-segment), Pseudomonas phage phiIBB-PF7A, Pseudomonas phage phikF77, Pseudomonas phage phiKZ, Pseudomonas phage PT2, Pseudomonas phage PT5, Pseudomonas phage SN, Pseudomonas phage phi297, Pseudomonas phage Bf7, Pseudomonas phage EL, Pseudomonas phageOBP, Pseudomonas phage PaP1, Pseudomonas phage 201phi21, Pseudomonas LUZ24, Pseudomonas phage phi-6 segment S, Pseudomonas phage phi8 segment S, Pseudomonas phage vB_PaeS_PMG1, and Enterobacteria phage phiKMV. [0050] Where the host bacteria is a Bacteroides, then the phage used in step (i) may be selected from examples of Bacteroides phage include phage of the Siphoviridae family such as Bacteroides phage B40-8 and Bacteroides phage B124-14. [0051] Where the host bacteria is a Propionibacterium, then the phage used in step (i) may be selected from examples of Propionibacterium phage include phage of the Siphoviridae family such as Propionibacterium phage PA6, Propionibacterium phage PAD20, and Propionibacterium phage PAS50. [0052] Where the host bacteria is a Mycobacterium, then the phage used in step (i) may be selected from examples of Mycobacterium include phage of the Siphoviridae and Myoviridae families. Particular examples of Mycobacterium phage include Mycobacterium phage Muddy, Mycobacterium phage Baee, Mycobacterium phage Girr, Mycobacterium phage Hamulus, Mycobacterium phage Mozy, Mycobacterium phage Omega, Mycobacterium phage Ramsey, Mycobacterium phage Soul22, and Mycobacterium phage St Annes. [0053] Where the host bacteria is a Yersinia, then the phage used in step (i) may be selected from examples of Yersinia such as those of the Myoviridae family. Particular examples of Yersinia phage include Yersinia phage phiR1-37. [0054] Where the host bacteria is a Gordonia, then the phage used in step (i) may be selected from examples of Gordonia such as those of the Siphoviridae family. Particular examples of Gordonia phage include Gordonia phage Smoothie. [0055] Further examples of suitable specific phage for use in step (i), and their respective bacterial "pair" (ie host bacteria) are shown in Table 1 below.
[0056] Table 1 Bacteriophage Host genus
Enterococcus phage vB_EfaP_Ef6.3 Enterococcus
Staphylococcus phage IME-SA2 Staphylococcus
St hl h ISP St hl
p g
Vib i i B V P SBP1 Vib i
[0057] The phage may be selected from available stocks of phage such as may be found in a "phage bank", or identified by screening natural sources of phage. The phage used to treat the host bacteria are referred to as the "entry phage". Those skilled in the art will be able to routinely identify a suitable amount of phage for the treatment of the host bacteria, but typically, the phage will be provided in an amount corresponding to a multiplicity of infection (MOI) value in the range of 0.05 to 2.0, more preferably about 0.5 to 1.2, and most preferably, of about 1.0. In this regard, the MOI may be 1.0 or more, 0.5 or more, 0.1 or more, or 0.001 or more, or less than 1.0, less than 0.1, or less than 0.01. [0058] The antibacterial agent used to treat the host bacteria in step (i) comprises protein synthesis inhibitor activity. Protein synthesis inhibitors (PSIs) may act via a mechanism of an interruption of peptide chain elongation, the blocking of the decoding site (A site) of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. Antibacterial agents such as PSI antibiotics are well known to those skilled in the art. [0059] In some embodiments, the antibacterial agent comprising protein synthesis inhibitory activity comprises an agent which binds to the 50S ribosomal subunit and inhibits protein synthesis by preventing peptide chain elongation. Examples include macrolides such as clindamycin, erythromycin, clarithromycin and azithromycin. [0060] In some embodiments, the antibacterial agent comprising protein synthesis inhibitory activity comprises an agent that can inhibit protein synthesis by blocking the A site of the 30S ribosomal subunit. Examples include kanamycin and streptomycin. [0061] Examples of protein synthesis inhibitors suitable for use in step (i) include spectinomycin, tetracycline, clindamycin, azithromycin, kanamycin, gentamicin, netilmicin, linezolid, chloramphenicol, capreomycin, mupirocin, dactinomycin, telithromycin, neomycin, lincomycin, fusidic acid, cethromycin, viomycin, sisomycin, puromycin and streptomycin. [0062] In some embodiments, the host bacteria is treated in step (i) with an amount of the antibacterial agent that is equal to or greater than the MIC, for example 2 x MIC, or 1 x MIC. [0063] In some embodiments, the host bacteria is treated in step (i) with a sub-inhibitory amount of at least one antibacterial agent. Those skilled in the art will be able to routinely identify a sub-
inhibitory amount of the antibacterial agent for the treatment of the host bacteria, but typically, where the antibacterial agent is an antibiotic such as an antibiotic to which the host bacteria is sensitive, the sub-inhibitory amount will be in the range of about 0.125 to 0.95 x MIC (minimum inhibitory concentration), more preferably about 0.125 to 0.65 x MIC and most preferably, about 0.5 x MIC ("½ MIC"). Other concentrations are, however, also contemplated. [0064] In some embodiments, the present disclosure provides a method of producing a modified phage, said method comprising the steps of: (i) treating a host bacteria insensitive to a selected phage strain (ie a phage non-sensitive, or phage insensitive, or phage resistant bacteria) with a suitable amount of the said phage strain and a sub- inhibitory amount of at least one antibacterial agent comprising protein synthesis inhibitor activity, and culturing the bacteria for a period and under conditions suitable for the phage to infect the bacteria and replicate to generate progeny phage; and (ii) recovering and expanding progeny phage which are phage with a modified capability to infect and cause lysis of said host bacteria. [0065] The treatment with the antibacterial agent may be performed concurrently with the phage treatment, before treatment with the phage, and/or after treatment with the phage. [0066] Typically, the treatment with the antibacterial agent is performed before the treatment with the phage (ie before the phage is added) in what is effectively a pre-treatment with the antibacterial agent. The pre-treatment with the antibacterial agent may be commenced up to 10 hours, more preferably up to 6 hours, more preferably up to 4 hours, more preferably up to 3 hours, prior to contacting the host bacteria with the entry phage. However, in some embodiments, the phage may be added first, then followed by the addition of the antibacterial agent. [0067] The host bacteria treated in accordance with step (i) are cultured for a period and under conditions suitable for the phage to infect the bacteria and replicate to generate progeny phage. Those skilled in the art are able to readily determine such a period and conditions. However, typically, the culture will be performed on standard growth media for 24 hours at 37oC. The progeny phage are also referred to as the "exit phage". Exit phage may be readily purified from the culture of step (i), if desired, by standard methodologies known to those skilled in the art including, for example, a purification process comprising centrifugation of the culture (to remove residual bacteria and bacterial cell walls etc. resulting from lysis) and filtration (eg by using a 0.2 μm syringe filter) to purify the phage particles. The purified exit phage may be used in step (ii) of the method. [0068] In step (ii) of the method of the first aspect, exit phage (progeny phage) that have a modified capability to infect and cause lysis and killing of the host bacteria (eg exit phage which show a
modified, enhanced, level of bactericidal activity against the host bacteria or "parent" used in step (i) relative to the entry phage) are recovered and propagated to expand the number of phage (ie the number of phage particles is increased) for subsequent use in, for example, a method of treating a subject requiring treatment for a bacterial infection or for storage in, for example, a phage bank. This may involve one or more steps (preferably, two or more steps) of culturing the host bacteria in the presence of the exit phage, or in other words, one or more steps of passaging the exit phage through the host bacteria. These culturing/passaging steps preferably do not include any treatment with the antibacterial agent as used in step (i) of the method, but may do so. Otherwise, the exit phage may be propagated by culturing/passaging with other sensitive bacteria to expand the number of phage. Phage particles that are present after these culturing/passaging steps represent modified exit phage that are capable of infecting and causing lysis of the host bacteria. Optionally, these exit phage may undergo one or more selection or analysis steps including, but not limited to: identifying exit phage with markedly enhanced lytic activity (eg to identify modified phage capable of infecting the parent bacteria only, but with at least a 500-fold or, more preferably, 1000-fold higher level of lytic activity; identifying exit phage with stability and/or growth (replication) characteristics that are substantially unchanged from that of the entry phage, except for a higher burst size; and/or identifying exit phage which encode and produce a lysin protein with markedly enhanced lytic activity which may involve, for example, assessing the relative lytic activity of the lysin protein produced by the modified phage (eg by expressing an isolated nucleic acid molecule encoding the lysin protein in a host bacteria: see for example the PHEARLESS assay described in the examples hereinafter) or through the sequencing of at least a lysin-encoding nucleotide sequence within the exit phage genome. It will be readily appreciated by those skilled in the art that the method of the first aspect may be performed in a multiple (parallel) format where different entry phage are separately used to treat different samples of host bacteria to generate different progeny exit phage; and the use of the optional one or more selection or analysis steps may then be used to identify a preferred exit phage from amongst the separately generated exit phage candidates. [0069] In some embodiments, the exit phage may be further propagated using the host bacteria or other sensitive phage to further expand the number of phage, such as for the purpose of storage in a phage bank. [0070] The method of the first aspect may be advantageous inasmuch as the use of repeated steps for the generation of modified phage may be avoided. Thus, step (i) preferably consists of no more than three steps, or no more than two steps, and more preferably only a single step of treating the insensitive host bacteria with a suitable amount of the selected phage strain and at least one antibacterial agent, and culturing the bacteria for a period and under conditions suitable for the phage to infect the bacteria and replicate to generate progeny phage. Moreover, in step (ii), where the exit phage is expanded (as described in paragraph [0068]), the steps of culturing/passaging are preferably
not conducted using the host bacteria in combination with at least the antibacterial agent that was used in step (i) or, more preferably, any other antibacterial agent comprising protein synthesis inhibitor activity. [0071] As such, the method of the first aspect may produce a modified exit phage to which the host bacteria has been re-sensitised, and which may be of use in (for example) treating a subject requiring treatment for a bacterial infection (ie in a phage therapy). Thus, in some embodiments, the method of the first aspect may be used to produce a modified exit phage which, unlike the selected entry phage, is capable of infecting and causing lysis of a host bacteria (such as a clinical isolate) causative of an infection being suffered by a subject. [0072] Thus, in some embodiments, the method of the first aspect is for producing a modified phage for use in a phage therapy of a subject's infection, and comprises the steps of: (i) treating a host bacteria that has been isolated from the said subject and which is insensitive to a selected phage strain (ie a phage non-sensitive bacteria) with a suitable amount of the said phage strain and at least one antibacterial agent comprising protein synthesis inhibitory activity, and culturing the bacteria for a period and under conditions suitable for the phage to infect the bacteria and replicate to generate progeny phage; (ii) recovering and expanding progeny phage which are phage with a modified capability to infect and cause lysis of said host bacteria; and (iii) providing the modified phage in a pharmaceutical composition for administration to the said subject. [0073] In some embodiments, the amount of the antibacterial agent comprising protein synthesis inhibitory is activity is a sub-inhibitory amount. [0074] Such embodiments enable a "personalised" approach to phage therapy which may be employed, for example, where a phage with an effective level of bactericidal activity against a bacteria causative of an infection in a subject, has either not been identified or is not readily available. As such, the method may enable the selection of an available phage that would normally be regarded as infectious for the bacteria if not for the circumstance that the particular bacterial strain concerned has become insensitive to the phage, and to use that phage as an entry phage from which to produce a modified exit phage that may then enable an effective phage therapy of the infection in the subject. [0075] Thus, in a second aspect, the present disclosure provides a method of treating a bacterial infection in a subject, said method comprising the steps of: 1. obtaining a sample of a bacteria causative of an infection in said subject, 2. treating the bacteria with a suitable amount of a selected phage strain to which the bacteria is
insensitive (ie the bacteria is phage non-sensitive) and at least one antibacterial agent comprising protein-synthesis inhibitory activity, and culturing the bacteria for a period and under conditions suitable for the phage to infect the bacteria and replicate to generate progeny phage; 3. recovering and expanding progeny phage which are phage with a modified capability to infect and cause lysis of said host bacteria; and 4. administering to the subject an effective amount of the progeny phage, or a further propagated form thereof, to treat the infection. [0076] In this second aspect, the present disclosure provides a method of treating a bacterial infection in a subject, the method comprising producing phage with improved lytic activity against a phage insensitive bacteria by exposing the insensitive host bacterium to a selected infecting phage and an agent having protein synthesis inhibitory activity and treating the infection with an effective amount of the phage with improved lytic activity. [0077] In some embodiments, the present disclosure provides a method of treating a bacterial infection in a subject, said method comprising the steps of: 1. obtaining a sample of a bacteria causative of an infection in said subject, 2. treating the bacteria with a suitable amount of a selected phage strain to which the bacteria is insensitive (ie the bacteria is phage non-sensitive) and a sub-inhibitory amount of at least one antibacterial agent comprising protein-synthesis inhibitory activity, and culturing the bacteria for a period and under conditions suitable for the phage to infect the bacteria and replicate to generate progeny phage; 3. recovering and expanding progeny phage which are phage with a modified capability to infect and cause lysis of said host bacteria; and 4. administering to the subject an effective amount of the progeny phage, or a further propagated form thereof, to treat the infection. [0078] The method of the second aspect may, particularly, be used to treat an infection in the subject which is not responding to antibiotic-based therapy (thereby indicating that the infectious bacteria is antibiotic drug-resistant) and/or treatment with phage (thereby indicating that the infectious bacteria is phage resistant or phage insensitive). The bacterial sample may be obtained from (eg isolated from), for example, a suitable body sample from the subject such as blood, urine, faecal sample, swab, or a tissue biopsy (eg a biopsy from a tissue at the site of infection). Bacteria present in the body sample may be isolated and expanded according to any of the standard methodologies known to those skilled in the art. The bacteria may optionally be identified by using standard methodologies including microscopy techniques, tests such as latex agglutination tests (see, for example, Essers L., J Clin Microbiol 12(5):641-643, 1980), MALDI and/or 16 S rRNA gene sequencing such as is well known to those skilled in the art. On the basis of the identification of the bacteria, a phage that would
normally be regarded as infectious for the bacteria may be selected from, for example, a phage bank for use as the "entry phage", however more typically, the selected phage will be a phage previously employed in a phage therapy on the subject (which was unsuccessful) or to which the causative bacteria has been found to be insensitive in, for example, a standard in vitro phage sensitivity test. The bacteria may be treated with the phage and antibacterial agent as described above in relation to the method of the first aspect. The treatment of the bacteria with the antibacterial agent is typically performed before the phage treatment. The step of recovering and expanding the progeny "exit phage" (eg to provide sufficient numbers of the modified exit phage for use in a phage therapy) may be carried out as described above in relation to the method of the first aspect. As such, the modified exit phage may also be further propagated using, for example, a sensitive bacterial strain, as required (eg for storage in a phage bank). For administration to the subject, the modified exit phage (or a further propagated form thereof) will typically be provided as a pharmaceutical composition comprising the phage in combination with at least one pharmaceutically acceptable carrier, diluent and/or excipient. The modified exit phage (or a further propagated form thereof) may be administered to the subject by any suitable route such as topical administration (eg for treatment of a surface wound), intramuscular administration (im) (eg by injection), intravenous administration (iv) (especially systemic infusion), oral administration or airway administration (eg by rinsing, nebulisation, spraying into the nose and paranasal sinuses and into the lungs in pulmonary administration). In some embodiments, the modified phage (or a further propagated form thereof) may be administered with one or more additional phage strain(s) (ie in a "phage cocktail") which may contribute to the effectiveness of the phage therapy in treating the infection, particularly in the case of a polymicrobial infection (ie where more than one bacteria strain is present in the infection). In addition, or alternatively, the modified phage (or a further propagated form thereof) may be used in a combination therapy with a suitable antibacterial agent. [0079] The method of the second aspect may be used to treat a bacterial infection in a subject, and especially a bacterial infection caused by bacteria showing drug-resistance and/or which is phage insensitive. In some embodiments, the method of the second aspect may be used to treat an infection in a subject caused by methicillin-resistant Staphylococcus aureus (MRSA) (eg a skin or lung infection, diabetic foot ulcer, sinus infection or sepsis), A. baumannii (eg an infection of the blood (bacteremia), lungs or urinary tract, or a wound infection by A. baumannii), C. difficile (eg a colon infection), P. aeruginosa (eg a lung infection, bacteremia, bone and joint infections, post-surgery infection, diabetic foot ulcers, sinus infection, ear infection), MDR strains of E.coli (eg an urinary tract infection (UTI)), an E. faecium such as vancomycin-resistant E. faecium (eg an infection of the blood (bacteremia), urinary tract, or of a wound), and Klebsiella spp. such as K. pneumoniae (eg an infection of the lungs or a UTI). Further, in one particular embodiment, the method of the second aspect may be used to treat sinusitis or rhinosinusitis (acute rhinosinusitis and chronic rhinosinusitis) which is commonly caused by S. aureus and/or P. aeruginosa.
[0080] In this specification, a number of terms are used which are well known to those skilled in the art. Nevertheless, for the purposes of clarity, a number of these terms are hereinafter defined. [0081] As used herein, the term "sub-inhibitory amount" refers to an amount (concentration) of an antibacterial agent which is below that required to detectably inhibit the growth and replication of a particular bacteria. The sub-inhibitory amount is a non-lethal amount for the particular bacteria. [0082] The term "minimum inhibitory concentration" is to be understood as it is to those skilled in the art. Therefore, as used herein, the term refers to the lowest amount (concentration) of an antibacterial agent that detectably inhibits the growth of a particular bacteria. [0083] The terms "phage non-sensitive", "phage insensitive" and "phage resistant" are used interchangeably to describe a characteristic of a particular bacteria to be insensitive to a certain phage or phages, such that phage(s) when contacted with the bacteria is unable to substantially infect and/or cause lysis of the bacteria (eg as may be detected by standard in vitro phage sensitivity test where lysis zones are assessed after spotting of phage onto a bacterial lawn on a standard petri dish or plate, and overnight culture). Such bacteria may be partially or fully resistant to the particular phage or phages. In contrast, phage contacted with "sensitive" bacteria will infect and/or cause lysis of the bacteria. [0084] The term "lysis" refers to a process whereby, for example, a phage or chemical agent causes the breaking down of the wall or membrane of a cell such as a bacterial cell leading to cell death. In the context of the present disclosure, the modified exit phage may show enhanced "lytic activity", meaning that the modified phage has an enhanced (increased) capability to cause lysis and/or killing of the host bacteria as compared to the entry phage. This lytic activity may be achieved, wholly or in part, by phage proteins known as "endolysins" (lysins) which are peptidoglycan-degrading or endopeptidase enzymes which can breakdown bacterial cell walls. [0085] As used herein, the term "treating" includes prophylaxis as well as the alleviation of established symptoms of an infectious disease or condition. As such, the act of "treating" an infection in a subject therefore includes: (1) preventing or delaying the appearance of clinical symptoms of the infectious disease or condition developing in a subject afflicted with the disease or condition; (2) inhibiting the infectious disease or condition (ie arresting, reducing or delaying the development of a bacterial infection or a relapse thereof (in case of a maintenance treatment) or at least one clinical or subclinical symptom thereof); and (3) relieving or attenuating the infectious disease or condition (ie causing regression of the bacterial infection or at least one of its clinical or subclinical symptoms). Treatment encompasses single or multiple treatments.
[0086] As used herein, the phrase "manufacture of a medicament" includes the use of the modified phage directly as a medicament, in combination with other additives, or in any stage of the manufacture of a medicament. [0087] The term "effective amount" refers to an amount sufficient to effect beneficial or desired clinical results (ie it is a "therapeutically effective amount"). A therapeutically effective amount can be administered in one or more administrations. Typically, a therapeutically effective amount is sufficient for treating an infectious disease or condition, or otherwise to palliate, ameliorate, stabilise, reverse, slow or delay the progression of such a disease or condition. By way of example only, a therapeutically effective amount of a modified phage produced in accordance with the method of the first aspect may comprise 104 to 1012 PFU, and more preferably 108 to 1010 PFU. However, notwithstanding the above, it will be understood by those skilled in the art that the therapeutically effective amount may vary and depend upon a variety of factors including the activity of particular phage(s), the age, body weight, sex and health of the subject, the route and time of administration of the modified phage, and the severity of, for example, the infectious disease or condition, and the type or types of bacteria causative of the infection. [0088] As mentioned above, the modified phage may be used in a combination therapy with a suitable antibacterial agent, in which case, the phage and antibacterial agent (eg an antibiotic) may be administered to the subject consecutively, together or in either order. As used herein, it is to be understood that when administered consecutively, the phage and antibacterial agent may be administered one after another with practically no time interval (ie one is administered effectively immediately after the other) or, otherwise, after an interval of 1 to 5 minutes or more (eg 10 minutes, 30 minutes, 60 minutes, 4 hours or 6 hours). Accordingly, in some embodiments, the phage and the antibacterial agent are provided in combination for administration in a single pharmaceutical composition. Such a pharmaceutical composition may further comprise, for example, a pharmaceutically acceptable carrier, diluent and/or excipient, and may be suitable for, for example, topical administration, intramuscular administration (im), oral administration or intravenous administration (iv). On the other hand, in some embodiments, where the phage and the antibacterial agent are administered consecutively, they may each be formulated for administration in a pharmaceutical composition form including a pharmaceutically acceptable carrier, diluent and/or excipient, which may be the same or different. Again, the pharmaceutical compositions may be suitable for, for example, topical administration, intramuscular administration (im), oral administration or intravenous administration (iv). [0089] In a third aspect, the present disclosure provides a modified phage produced in accordance with the method of the first aspect. The phage may be further propagated using, for example, a sensitive bacterial strain, as required.
[0090] In a fourth aspect, the present disclosure provides a pharmaceutical composition comprising a modified phage produced in accordance with the method of the first aspect, or a further propagated from thereof, optionally in combination with at least one pharmaceutically acceptable additive, carrier, diluent and/or excipient. [0091] Such a pharmaceutical composition may also comprise one or more additional phage strain(s) (ie in a "phage cocktail") and/or a suitable antibacterial agent (ie for a combination therapy). In addition, the pharmaceutical composition may optionally comprise other substances such as absorption enhancers including surfactants (eg sodium lauryl sulphate, laureth-9, sodium dodecylsulphate, sodium taurodihydrofusidate and poly oxyethylene ethers), chelating agents (eg EDTA, citric acid and salicylates), and preservatives (eg sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid) and/or suitable binders, lubricants, suspending agents, coating agents and solubilising agents. Examples of suitable binders include starch, gelatin, natural sugars such as glucose, anhydrous lactose, free-flow lactose, beta-lactose, corn sweeteners, natural and synthetic gums, such as acacia, tragacanth or sodium alginate, carboxymethyl cellulose and polyethylene glycol. Examples of suitable lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. [0092] The at least one pharmaceutically acceptable additive, carrier, diluent and/or excipient may be selected from any of the suitable additives, carriers, diluents and excipients that are well known to those skilled in the art, and which are described in, for example, Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA 1995. Particular examples of suitable carriers include lactose, starch, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol and the like. Examples of suitable diluents include ethanol, glycerol and water. Particular examples of suitable excipients may be found in the Handbook of Pharmaceutical Excipients, 2nd Edition, (1994), Edited by A Wade and PJ Weller. [0093] The pharmaceutical compositions may be intended for single daily administration, multiple daily administration, or controlled or sustained release, as needed to achieve the most effective results. [0094] Examples of pharmaceutical compositions include compositions suitable for delivery by injection, compositions suitable for intravenous administration, compositions suitable for delivery by topical administration, compositions suitable for delivery via a gel, and compositions suitable for pulmonary delivery. For example, a suitable composition for topical delivery may comprise a requisite concentration of phage in PBS, in water or in SM buffer (To prepare: NaCl, 5.8 g, 100 mM ; MgSO4•7H2O 2 g, 8 mM ; Tris-Cl (1 M, pH 7.5), 50 ml, 50 mM ; H2O to 1 liter).
[0095] In a fifth aspect, the present disclosure provides the use of a modified phage produced in accordance with the method of the first aspect, or a further propagated form thereof, in the manufacture of a medicament for treating an infection in a subject. Methods for manufacturing medicaments are known in the art. [0096] In a sixth aspect, the present disclosure provides a modified phage, produced in accordance with the method of the first aspect, or a further propagated form thereof, for treating an infection in a subject. [0097] Examples of diseases or conditions suitable for treatment with a modified phage are described herein include sinus conditions (eg acute rhinosinusitis and chronic rhinosinusitis), respiratory conditions (eg lung infections, cystic fibrosis), ear conditions (infections of the external ear canal or of the middle ear), diabetic ulcers (eg diabetic foot ulcers), sepsis or a skin infection (eg Staphylococcus skin infections). Other diseases or conditions are contemplated. [0098] The modified phage of the present disclosure is typically applied to the treatment of an infectious disease or condition in a human subject. However, the subject may also be selected from, for example, livestock animals (eg cows, horses, pigs, sheep and goats), companion animals (eg dogs and cats) and exotic animals (eg non-human primates, tigers, elephants etc). [0099] In a seventh aspect, the present disclosure provides a method of killing bacteria, said method comprising contacting the bacteria with a modified phage produced in accordance with the method of the first aspect or a further propagated form thereof. [00100] The method of the seventh aspect may be conducted in, for example, a laboratory setting where, for example, the method may be used to prevent bacterial contamination, and other situations where bacterial infections or contaminations can occur (eg industrial and environmental situations). In some embodiments, the method of the seventh aspect may be used for decontaminating surfaces and equipment such as food preparation surfaces and equipment, and medical and surgical surfaces and/or equipment etc. The bacteria for killing may be present in a planktonic or biofilm form. [00101] As described herein, the method of the seventh aspect may also be used for the treatment of a subject. [00102] As mentioned above, the modified phage produced in accordance with the method of the first aspect, are capable of infecting and causing lysis of the parent host bacteria. In some embodiments, the modified phage may show markedly enhanced lytic activity of a level which is at least 1000-fold
higher than that of the entry phage. Such modified phage may express a novel lysin protein with markedly enhanced lytic activity. [00103] Thus, in an eighth aspect, the present disclosure provides an isolated phage lysin protein (an endolysin) derived from a modified phage produced in accordance with the method of the first aspect. [00104] The lysin protein may also be formulated into a composition, such as a pharmaceutical composition for use in treating a bacterial infection in a subject (such as those described above), or for killing bacteria in other situations such as environmental contaminations, or for decontaminating surfaces and equipment such as some of those mentioned above including food preparation surfaces and equipment, surgical equipment and air conditioning systems etc. [00105] Standard techniques and equipment may be used for recombinant DNA technology, DNA sequencing, oligonucleotide synthesis, molecular biology, cell biology and enzymatic reactions, which may be generally performed according to methods known in the art and/or as commercially available, and are as described for example in Sambrook et al. Molecular Cloning: A Laboratory Manual (4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)) and Ausubel et al Current Protocols in Molecular Biology (2003) John Wiley & Sons, both of which are herein incorporated by reference. [00106] The methods, phage and phage proteins (lysins) of the present disclosure are hereinafter further described with reference to the following non-limiting examples and accompanying figures. EXAMPLES Example 1 [00107] The study described in this example aimed to evaluate whether specific antibiotics could sensitise phage non-sensitive S. aureus isolates to phage infection in vitro and in vivo. Materials and Methods [00108] Phages, clinical isolates and antibiotics S. aureus ATCC51650 and ATCC25923 were obtained from the American Type Culture Collection (Manassas, VA, United States of America) and used as reference strains. In addition, a total of 15 S. aureus clinical isolates (CIs) were isolated from the sinonasal cavities of chronic sinusitis (CRS) patients. In each case, S. aureus was cultured by an independent diagnostic laboratory and the antibiotic susceptibility determined by disc diffusion on Mueller-Hinton agar per Clinical and Laboratory Standards Institute (CLSI) recommendations (Adelaide Pathology Partners, Mile End, SA,
Australia). Bacteria were isolated on Columbian horse blood agar plates, colistin nalidixic acid plates, or cystine lactose electrolyte–deficient plates (Oxoid Australia Pty Ltd, Thebarton, SA, Australia). Positive cultures were confirmed to be S. aureus using latex agglutination testing. Phages J-Sa36 (Sa36), Sa83 and Sa87 were obtained from AmpliPhi Australia Pty Ltd (Brookvale, NSW, Australia). [00109] Antibiotic sensitivity testing The minimum inhibitory concentration (MIC) of amoxicillin, vancomycin, erythromycin, clindamycin and azithromycin against the S. aureus strains was assessed using the broth microdilution technique as previously described (Wiegand I et al., Nature protocols 3(2):163-175, 2008) and breakpoints defined according to CSLI guidelines. Clinical strains resistant to at least one antibiotic in three or more antibiotic categories were defined as multidrug resistant (MDR). [00110] Phage sensitivity test The sensitivity of S. aureus isolates (15 clinical isolates and 2 ATCC strains) to phages J-Sa36, Sa83 and Sa87 was determined as previously described (Drilling A et al., Am J Rhinol Allergy 28(1):3-11, 2014). Briefly, 0.5 McFarland Units of S. aureus CIs diluted 1:100 in 10 ml Tryptic soy broth (TSB) were grown overnight at 37°C with shaking.200 μL of overnight broth cultures were then spread onto Columbian blood agar plates evenly (Oxoid). Plates were incubated at 37°C for 1 hour and 5 μL [106 plaque forming units (PFU)] of 3 phages were spotted in triplicates onto the plates and incubated at 37°C overnight. Phage buffer solution (SM buffer) alone was spotted in the centre of the plates as negative control. Phage sensitivity was determined according to the protocol described in Zhang G et al., editors. Bacteriophage effectively kills multidrug resistant Staphylococcus aureus clinical isolates from chronic rhinosinusitis patients. International Forum of Allergy & Rhinology; 2018: Wiley Online Library. Confluent lysis zones observed on plates were defined as phage sensitive, semi-confluent lysis zones were defined as phage semi-sensitive, and no plaques were defined as phage insensitive (non-sensitive). [00111] Determining the effect of phage combined with antibiotics on planktonic S. aureus Initial screening was performed in 100 μl in 96 well plates, with follow up experiments in 10 mL culture volume. S. aureus strains were grown on 1.5 % Tryptone Soya Agar (TSA) at 37°C overnight. Single colonies were transferred to Tryptone Soya Broth (TSB) to generate a culture with a starting concentration of 5 x 105 CFU/ml. Phage J-Sa36, Sa83 and Sa87 were added to the cultures at multiplicity of infection (MOI) of 0.2 according to predetermined phage titers (described below). Antibiotics were added to the cultures at ½ MIC (according to the pretest MIC of antibiotics) if required. Optical density (OD) readings at 600 nm were recorded at 24 hours to assess the growth of bacteria co-inoculated with phage unless otherwise specified. Uninoculated, fresh media was included as a sterility control.
[00112] Determination of phage titers Phage titers were determined against S. aureus RN4220 (ATCC) using the double layer spot assay technique. Briefly, 100 µl of a S. aureus overnight culture was mixed with 4 mL of 0.4% TSA and poured onto a 1.5 % TSA plate. After 20 minutes, serially diluted samples of phage J-Sa36, Sa83 or Sa87 were spotted onto the double layer agar plates in 5 µl spot volumes in triplicates. After the plates were incubated in a humidified incubator at 37°C overnight, plaques were counted, counts were averaged, and titers of the filtrate were calculated based on the dilution. [00113] Determining phage replication by titer A 100 ^l sample was taken from an S. aureus culture (10 ml in TSB) after 0 and 48 hours following treatment with clindamycin, phage or a phage clindamycin co-incubation. The sample was treated with 25µl of chloroform, shaken for 30 seconds, centrifuged (3000 rpm, 5 minutes, room temperature) and the supernatant used to determine phage titers against the same isolate. Phage titers in plaque forming units [PFU]/ mL were recorded initially and at 48 hours to assess for phage replication. To allow for phage resistant (phage insensitive) bacterial isolates to show plaques, clindamycin was added to the soft agar overlay. [00114] Determining the effect of phage in combination with clindamycin o S. aureus biofilms
The effect of J-Sa36, Sa83 and Sa87 combined with clindamycin was tested on S. aureus biofilms formed by ATCC51650 and clinical isolate 11 (CI11). Briefly, a 1.0 McFarland unit S. aureus culture suspended in 1:15 dilution in TSB was added to 96-well microtiter plates (Costar; Corning Incorporated, Corning, NY, United States of America). Plates were incubated for 48 hours at 37°C on a rotating platform at 70 rpm (3D Gyratory Mixer; Ratek Instruments, Boronia, VIC, Australia) to allow biofilm formation followed by washing with phosphate-buffered saline. Biofilms were then treated with 8 x106 plaque forming units (PFU) of phage J-Sa36, Sa83 or Sa87 and clindamycin added with a final concentration of 1 μg/ml, 0.5 μg/ml, 0.2 μg/ml, 0.1 μg/ml, or 0.05 μg/ml, in TSB. Wells were treated for 24 hours at 37°C with gentle shaking. The AlamarBlue viability assay (Thermo Fisher Scientific, Waltham, MA, United States of America) was used as previously described (Richter K et al., editors. Mind "De GaPP": in vitro efficacy of deferiprone and gallium‐protoporphyrin against Staphylococcus aureus biofilms. International Forum of Allergy & Rhinology; 2016: Wiley Online Library to determine the anti-biofilm activity of the phage. Fluorescence was measured in a microplate reader (FLUOstar OPTIMA, BMG LABTECH, Offenburg, Germany) and the percent reduction of biofilm after treatment determined relative to untreated controls. [00115] Time-dependent effect of the interaction of phage J-Sa36 and clindamycin in S. aureus (1) ATCC51650 or CI11 was incubated with ½ MIC clindamycin in 10ml TSB, then phage J-Sa36 (1×105 PFU/ml) was added into the above at different times (1h, 2h, 3h, 3.5h, 4h, 6h and 24h) and incubated for 24 hours. OD600 readings were taken at phage addition and following 24-hour
incubation. (2) ATCC51650 or CI11 was incubated with either ½ MIC clindamycin or phage J-Sa36 (MOI=0.2) for 3.5 hours followed by the addition of phage J-Sa36 (1×105 PFU/ml, MOI=0.2) or ½ MIC clindamycin respectively and continuous incubation with both ½ MIC clindamycin and phage J-Sa36 for 24 hours. OD600 readings were taken at addition of either phage or clindamycin and following the 24-hour incubation. The total amount of phage J-Sa36 added into the culture at different time points was adjusted to maintain MOI=0.2, according to the number of bacteria measured via CFU counts at each time point. [00116] Selection and preparation of the S. aureus clinical isolates for inoculation An S. aureus clinical isolate (CI3) was selected for in vivo experiments that was sensitive to both antibiotics to be used, insensitive to Sa87 phage on planktonic inhibition assays and could be sensitised to phage in the presence of both antibiotics in vitro. A fresh culture of CI3 on 1.5% TSA plates was prepared two days before inoculation. A single colony was resuspended in 0.9 % saline (ca. 2ml) to turbidity reading 0.5 McFarland Units and then a 1 in 100 dilution in TSB was cultured overnight one day before the in vivo experiment. CI3 pellets were harvested and resuspended in fresh TSB to reach 2.5 x 109 Colony Forming Units (CFU)/ml. [00117] In vivo safety study Nine Specific Pathogen Free (SPF) Sprague Dawley rats (6 weeks old, males) were administered (n=3 rats/group)(23) 20 μl (1) Sa87 (0.5 x 1010 PFU/ml) + ½ MIC Clindamycin in saline, (b) Sa87 (0.5 x 1010 PFU/ml) + ½ MIC Azithromycin in saline or (3) saline. Treatments were administered intranasally twice a day for 21 days, the general wellbeing of the rat (including its appetite, behaviour, and any weight change) being closely monitored. The rats were then sacrificed and the sinus mucosal tissue, lungs, heart, liver, kidneys, spleen and brain harvested. Tissue was divided and kept fresh or 10% formalin-fixed, the latter then processed to paraffin wax, and 6 µm sections cut and stained with haematoxylin and eosin (H&E) for histopathological examination. Formalin fixed tissue was embedded in paraffin and processed to undergo H&E staining and histopathological analysis. The fresh sinus mucosa, lungs, heart, liver, kidneys, spleen, and brain were all analysed for phage titers. Faecal samples were collected from all the rats prior to the administration of the first treatment, as well as every day thereafter for phage titers.500 μl blood samples were collected from the rat tail vein prior to the first treatment and again at 1, 2, 4 and 6 hours following the morning treatment on day 7 and 14 of treatment. This was repeated at 1, 2, 4, 6, 12, 24 and 48 hours following the last treatments on Day 21. [00118] Phage titers in faeces and organ tissues 1 g of faeces was suspended in 10 mL of SM buffer, centrifuged at 3214 × g for 10 minutes (Eppendorf 5810 centrifuge, North Ryde, NSW, Australia),filtered (0.22 μm), and titrated for phage
concentration. 1g of rat faeces was collected from every rat at day 0 and daily after the first treatment, and directly placed into 5 mL SM buffer. Further, following killing, the rat frontal sinus mucosa was dissected and placed directly into 5 mL SM buffer.1cm x 1cm pieces of organ were collected from the brain, lungs, heart, liver, kidney and spleen and were also placed into 5 mL SM buffer. Phage titers and enrichment were performed as previously described (Drilling et al., 2014 supra). Briefly, organ and sinus tissues were ground in 5mL SM buffer using a Qiagen TissueRuptor (Qiagen, Hilden, Germany). All tissue samples were then centrifuged at 3000 g for 10 minutes, filtered through a 0.22μm of syringe filter (Pall Corporation, San Diego, CA, United States of America), and titrated for phage.1g of faeces was suspended in 5 mL of SM buffer, centrifuged at 3214 × g for 10 minutes (Eppendorf 5810 centrifuge),filtered using a 0.22μm filter, and titrated for phage concentration. For phage enrichment, 100μL of 0.5 McFarland Units of S. aureus RN4220 diluted 1:100 with 10 ml TSB was grown overnight at 37◦C with shaking. Samples (1ml tissue and faeces supernatants) were then incubated overnight with 5ml TSB and 50μL of S. aureus RN4220 overnight culture. The enriched samples were then centrifuged and filtered using a 0.22μm filter, then titrated for phage. Phage titers were determined against S. aureus RN4220 using the double layer spot assay technique as described above. [00119] Phage titer in the blood sample 500 μl of blood was collected from the rat tail vein. Blood tubes were centrifuged at 1000 rpm for 20 minutes at 4°C. The plasma was then harvested and filtered through a 0.22μm syringe filter. Phage enrichment was then performed, as above. [00120] Histopathology Rat nasal tissues were fixed in 10% neutral buffered formalin. Tissue samples were then decalcified using 9.5% nitric acid in 1% ethylenediaminetetracetic acid (EDTA), processed to paraffin wax, and 6 μm sections cut and stained with H&E. The samples were examined by a veterinary pathologist blinded to the treatments given. [00121] Efficacy arm protocol An established murine rhinosinusitis model was used with modifications (see YU C-j et al., Chinese Journal of Otorhinolaryngology-Skull Base Surgery 6, 2011; Zhang F et al., Am J Rhinol Allergy 27(5):361-366, 2013; and Jin M et al., Eur Arch Oto-Rhino-L 268(6):857-861, 2011). Thirty Sprague Dawley rats (6 weeks old, males) underwent general anaesthesia and placement into the right nasal cavity of a 10mm × 0.5mm × 0.5mm sponge (Gyrus ACMI, MA, United States of America), soaked in a 20 μl 0.5 x 108 CFU S. aureus CI3 solution (sensitive to clindamycin and azithromycin but insensitive to Sa87), diluted in 0.9% saline. The sponges were placed at approximately 15 mm from the anterior nostril, located in the ostiomeatal complex. The rats were monitored for a nine-day period to allow for mucosal biofilms to form, and, on the tenth day, the sponges were removed. A two-day
recovery was given to the rat before treatments begun. The rats were then randomised into one of 6 treatment groups (n=5 rats each) to receive 20 μl (1) Sa87 (0.5 x 1010 PFU/ml) + ½ MIC clindamycin in saline, (2) Sa87 (0.5 x 1010 PFU/ml) + ½ MIC Azithromycin in saline, (3) Sa87 (0.5 x 1010 PFU/ml in saline), (4) ½ MIC Clindamycin in saline, (5) ½ MIC Azithromycin in saline, and (6) saline. Treatments were administered intranasally twice a day for 14 days. Rats were monitored for weight and respiratory alterations (respiration rate; nasal discharge, hyperaemia or pruritus; and sneezing) during treatment, and, 14 days post-treatment initiation, the rats were humanely sacrificed. Their sinus mucosa was harvested for CFU counting, biofilm quantification, histopathology, and phage enumeration. [00122] Colony-forming unit (CFU) counting of sinus mucosa A fresh (0.2 x 0.2cm) piece of sinus mucosa was harvested and directly placed in 250μl 0.9% saline. The mucosa was then homogenised on the highest setting for 30 seconds, or underwent vortex mixing on the highest setting for two minutes. The homogenised supernatants were then serially diluted in 0.9% saline and spotted on sheep blood agar in triplicates (Beckton Dickenson, Franklin Lakes, NJ, United States of America) and incubated at 37oC overnight for CFU counting of S. aureus. [00123] Biofilm biomass quantification on sinus mucosa The quantification of biofilm biomass on sinus mucosa was determined using an established protocol (Singhal D et al., editors. Quantitative analysis of in vivo mucosal bacterial biofilms. International Forum of Allergy & Rhinology; 2012: Wiley Online Library (27). Briefly, the frontal sinus mucosa was harvested and placed into Dulbecco’s Modified Eagle’s Medium (Life Technologies, Carlsbad, CA, United States of America) on ice. One piece of mucosa from each frontal sinus was stained with a LIVE/DEAD® BacLight Bacterial Viability Kit (Life Technologies Australia). The stained mucosa was then examined at 20X magnification using a confocal laser scanning microscope (Zeiss LSM700, Carl Zeiss AG, Oberkochen, Germany). The z-stack images (21 slices, interval 1 µm) were then taken from each sample and, COMSTAT Version 2.1 software was used to measure the biomass of biofilms, the threshold setting being applied so as to minimise background staining (Heydorn A et al., Microbiology 146(10):2395-2407, 2000). [00124] Post-treatment sinus microbiology analysis A fresh (0.2 x 0.2 cm) piece of mucosa from each rat sinus was harvested and homogenised in 0.9% saline. The supernatant was then harvested and transferred into a new tube without centrifugation. The collected supernatant was serially diluted and plated on blood agar plates in triplicates. After overnight incubation at 370C, different bacterial colonies (according to the morphology and haemolytic reaction) were sub-cultured on Mannitol salt agar. Positive colonies on the Mannitol salt agar were confirmed to be S. aureus with a Staphylase Test Kit (Oxoid). Other colonies with different morphologies were further identified using MALDI-TOF (Bruker, VIC, Australia).
[00125] Post-treatment sinus S. aureus phage sensitivity S. aureus isolates, cultured from the sinuses of rats, were sub-cultured and tested for sensitivity to phage Sa87 using the phage sensitivity test as specified above. [00126] Statistical analysis GraphPad Prism (GraphPad Prism version 8.00; GraphPad Software, La Jolla, CA) was used to graph and analyse statistical significance of data. Statistical significance for in vitro and in vivo results was computed using a one-way analysis of variance (ANOVA) or mixed ANOVA. Significance was determined at a p-value < 0.05. Results [00127] Synergism of phages combined with antibiotics to kill S. aureus in vitro Of the 17 S. aureus isolates, the two ATCC strains and 10 of the 15 CIs were sensitive or showed intermediate sensitivity to all five antibiotics tested (ie amoxicillin, vancomycin, erythromycin, clindamycin and azithromycin). A further three isolates exhibited resistance to only erythromycin, two isolates exhibited resistance to azithromycin and two exhibited multidrug resistance. The isolates were also tested for susceptibility to the three phages, J-Sa36, Sa83 and Sa87. J-Sa36 was active in vitro against only 2/17 strains tested (sensitive strains); 2/17 strains were semi-sensitive and 13/17 strains were insensitive (resistant). The in vitro activity observed for Sa83 and Sa87 was considerably higher; for Sa83, 11/17 isolates were sensitive or semi-sensitive and 6/17 insensitive and for Sa87, 12/17 isolates were sensitive or semi-sensitive and 5/17 insensitive. [00128] To evaluate if the combination of phage and antibiotics would be more effective than either treatment alone, the phage (ie J-Sa36, Sa83 or Sa87 (MOI = 0.2)) in combination with ½ MIC of all 5 antibiotics against nine isolates were screened. S. aureus ATCC51650 and CIs (CI2, CI3, CI4, CI6, CI7, CI8, CI9, and CI11) were selected to represent a range of phage sensitivities. All nine isolates were either resistant (7/9) or semi-sensitive (2/9) to phage J-Sa36 alone, whilst 4/9 and 5/9 were resistant or semi-sensitive to the phages Sa83 and Sa87. A synergistic effect was defined as a statistically significant decrease in optical density (OD) that was larger than the combined decrease in OD of antibiotic and phage only controls. None of the combinations of phage with either of the cell wall actives (amoxicillin and vancomycin) showed any significant additive or synergistic effects. However, in contrast, all nine isolates showed synergism with the combination of a PSI antibiotic (erythromycin, clindamycin and azithromycin) and at least one phage. The results for one representative isolate, namely S. aureus CI3, are shown in Figure 1. [00129] Particularly, the combination treatment of J-Sa36 with ½ MIC clindamycin and azithromycin showed synergistic effects against six of the nine phage non-sensitive and semi-sensitive isolates, with
erythromycin showing synergistic effects in five of the nine isolates. For those isolates that were insensitive to Sa83, the addition of ½ MIC of erythromycin, clindamycin and azithromycin significantly improved antimicrobial activity in three out of the four isolates screened. Further, for isolates insensitive or semi-sensitive to Sa87, the addition of ½ MIC erythromycin, clindamycin and azithromycin improved the antimicrobial activity in four out of five (for erythromycin) and all five (for clindamycin and azithromycin) insensitive and semi-sensitive isolates (see Table 2 below). As clindamycin was the most effective antibiotic in combination with all three phage types, further investigation was focused on this antibiotic. [00130] Table 2: Summary of screening of antibiotic and phage combinations to kill S. aureus
Effects were characterised as resistant (-) if no significant difference in OD was observed compared to untreated control, semi-sensitive (±) if a significant difference was observed but OD remained ≥ 10% of untreated control, sensitive (+) if growth remained < 10% of untreated control and synergistic (+) with shading if both sensitive and significantly reduced compared to antibiotic and phage only controls. Dark grey represents synergistic effects against phage resistant strains; light grey represents synergistic effects against semi-sensitive strains. [00131] Dose-dependence of clindamycin in combination with phage J-Sa36 to kill S. aureus J-Sa36 semi-sensitive and insensitive isolates ATCC51650 (MIC=0.2μg/ml) and CI11 (MIC=0.2μg/ml) were each co-incubated with J-Sa36 phage and a range of clindamycin concentrations to determine the minimum dose of clindamycin required for facilitating phage J-Sa36 anti-microbial activity. Incubation with 0.025μg/ml (1/8 MIC), 0.05μg/ml (1/4 MIC) or 0.1μg/ml (½
MIC) in combination with J-Sa36 equally reduced OD values compared to positive controls after 24 hours incubation (p<0.01). The lowest effective concentration of clindamycin required to facilitate phage J-Sa36 killing of ATCC51650 and CI11 was 0.025μg/ml, 1/8th the MIC. Lower (0.01μg/ml or 0.005μg/ml) clindamycin concentrations combined with J-Sa36 showed no significant reduction in OD compared to either the J-Sa36 only treatment or medium only control. The results are shown in Figure 2. [00132] The effect of phage on S. aureus biofilms with and without clindamycin Clindamycin alone significantly reduced the viability of preformed ATCC51650 and CI11 biofilms at a concentration of 0.5 μg/ml (MIC=0.2 μg/ml) and above, with lower concentrations having no significant effect on biofilm viability. Treatment with phages J-Sa36, Sa83 or Sa87 (PFU=8 x 106/ml) alone did not affect CI11 biofilm viability, and J-Sa36 did not affect ATCC51650 biofilm viability. However, the combination of ≥ 0.1μg/ml (½ MIC) clindamycin with J-Sa36, Sa83 or Sa87 significantly reduced the viability of ATCC51650 and CI11 biofilms, compared to untreated, clindamycin only and phage only controls. The combination reduced the required concentration of clindamycin to significantly reduce biofilm viability by five-fold. The results are shown in Figure 3. [00133] Clindamycin-dependent increase in phage infectivity in S. aureus is constrained in time To determine if phage were sensitising S. aureus isolates to clindamycin or if clindamycin treatment was facilitating phage infection of S. aureus phage insensitive and semi-sensitive strains, both ATCC51650 and CI11 in liquid culture were incubated with either ½ MIC clindamycin or phage J- Sa36 (MOI 0.2) for 3.5 hours. Following this, the alternate treatment was added before continuous incubation with ½ MIC clindamycin and phage J-Sa36 for 24 hours. As shown in Figure 4 (A-B), incubation with ½ MIC clindamycin or J-Sa36 only did not significantly affect bacterial viability at 24 hours. However, pre-incubation of ATCC51650 or CI11 with ½ MIC clindamycin for 3.5 hours, followed by incubation with J-Sa36 resulted in almost complete eradication of both ATCC51650 and CI11 after 24 hours. Reversing the sequence of challenge, namely incubation of the strains with J- Sa36 for 3.5 hours followed by incubation with ½ MIC clindamycin for 24 hours, resulted in a smaller but still significant reduction (p <0.01) in OD compared with untreated control. To confirm the time- dependent effects of this co-treatment, ATCC51650 or CI11 were also incubated with ½ MIC clindamycin in 10ml TSB, then phage J-Sa36 was added into the above at different times (1h, 2h, 3h, 3.5h, 4h, 6h and 24h) (with the phage adjusted at the different time points to maintain MOI=0.2). Following 24 hours incubation, significantly reduced OD600 values were observed for cultures where J-Sa36 was added up to 4 hours post-clindamycin challenge but not when J-Sa36 was added 6 and 24 hours after challenge (see Figure 4 (C-D)). [00134] Sub-inhibitory (below MIC concentrations) clindamycin enhances phage activity
To determine whether clindamycin enhanced phage activity or induced an endogenous prophage, phage titers were determined from cultures of ATCC51650, CI11 and CI8 after incubation for 48 hours with ½ MIC clindamycin, phage or both.100μl of the resulting culture was then chloroform treated to release phage and the supernatant used to determine phage titers using ATCC51650, CI11 and CI8 as host. The initial phage inoculum of 104 PFU/ml at 0 hours generated plaques only against ATCC51650 in the presence of clindamycin in the agar overlay, but no plaques were observed for CI11 or CI8. This indicates that a high MOI might be required in addition to clindamycin to facilitate phage lysis in these strains. The supernatant of the isolates exposed to ½ MIC clindamycin only for ATCC51650, CI11 and CI8 produced no plaques in any of the strains after 48 hours incubation, indicating that no intact prophages that could lyse those isolates were induced by clindamycin treatment. For the phage only treatment groups, J-Sa36 added to ATCC51650 produced no significant increase in phage titer and CI11 produced no plaques, indicating that J-Sa36 cannot infect and replicate in these isolates in the absence of clindamycin. Similar results were observed for phage Sa83; with phage only treatment of CI11 for 48 hours not producing any plaques. In contrast, co-treatment of ½ MIC clindamycin and phage led to increased phage titers in all cases. For instance, after 48 hours, ATCC51650 treated with J-Sa36 and ½ MIC clindamycin showed a concentration increase from ~104 PFU/ml to 7.73 ± 2.14×106 PFU/ml. This result indicates that a clindamycin-mediated phage infection is capable of producing new phage particles, not simply leading to host cell death. The same result was observed for CI11 treated with J-Sa36 and ½ MIC clindamycin (1.9 ± 1.3×109 PFU/ml), and Sa83 and ½ MIC clindamycin (6.4 ± 2.6×107 PFU/ml). Whilst the same trend was also observed for CI8 with Sa83 and ½ MIC clindamycin, a semi-confluent plaque was observed only at higher concentrations making quantification of titer impossible. [00135] Sub-inhibitory PSI antibiotics sensitise S. aureus insensitive strains to phage in vivo From the 30 rats across the treatment groups, 27 completed the study protocol (nb.1 rat from the azithromycin group and 2 rats from the saline control group died due to ketamine intoxication). After two weeks of twice daily topical application of test treatments, control saline-treated rats had similar S. aureus CFU counts/ml compared to rats treated with 0.5 x 1010 PFU/ml Sa87, ½ MIC clindamycin or ½ MIC azithromycin (p > 0.05). Sensitivity testing indicated similar sensitivity to the antibiotics and insensitivity to Sa87 for the post- and pre-treatment S. aureus isolates. In contrast, no S. aureus were cultured in rats treated with 0.5 x 1010 PFU/ml Sa87 in combination with ½ MIC clindamycin or azithromycin and were significantly lower than control saline-treated rats or rats treated with Sa87 or ½ MIC clindamycin or azithromycin (p=0.0086) (see Figure 5A). However, bacterial colonies that were not S. aureus were grown from the nasal mucosa of those rats (CFU counts of <500 CFU/mL). MALDI-TOF analysis identified those bacteria to be E. coli and E. faecalis. Biofilm biomass quantitation showed similar biomass quantities in controls, Sa87 and ½ MIC clindamycin treated rats and a significant increase in biomass in ½ MIC azithromycin treated rats as compared to control. In
contrast, there was a significant reduction in biofilm biomass in rats treated with 0.5 x 1010 PFU/ml Sa87 in combination with ½ MIC clindamycin or azithromycin compared to control (p<0.0001) (see Figure 5B); and confocal laser microscopy of mucosa stained with a LIVE/DEAD® BacLight Bacterial Viability Kit (Life Technologies Australia) clearly revealed dead (PI, red) and live (SYTO® 9, green) biofilm associated bacteria in samples representative of each treatment group). In addition, histopathology of the maxilloturbinates by a pathologist, blinded to the treatment given, showed normal ciliated pseudostratified respiratory epithelium with no evidence of inflammation or glandular hyperplasia in rats treated with Sa87 in combination with ½ MIC clindamycin or azithromycin. In contrast, in rats treated with Sa87, ½ MIC clindamycin, ½ MIC azithromycin or saline only, there was evidence of cilial denudation and surface epithelial erosion, with desquamated necrotic luminal cellular debris admixed with neutrophils. The lamina propria was congested and oedematous and contained a more robust mixed inflammatory cell infiltrate, which also infiltrated the lining epithelium. Discussion [00136] This study showed that sub-inhibitory (below MIC values) concentrations of PSI antibiotics (particularly, erythromycin, clindamycin and azithromycin) can sensitise phage non-sensitive and semi-sensitive S. aureus clinical isolates to phage infection. Sensitisation also occurred in vivo, leading to eradication of phage non-sensitive S. aureus biofilms in the presence of both antibiotics and phage. Example 2 [00137] The study described in this example aimed to provide further evidence that sub-inhibitory concentrations of PSI antibiotics can sensitise phage non-sensitive S. aureus to phage infection, and additionally, provide some characterisation of the progeny phage (exit phage). Materials and Methods [00138] Bacterial strains and growth conditions S. aureus strains frozen stocks were thawed and streaked on 1.5% trypticase soy agar (TSA) (Oxoid) plates at 37℃ overnight. A single colony was picked and resuspended in 2ml 0.9% saline to achieve McFarland (McF)=0.5.100 µl of resuspended bacterial solution was then added into 10 ml trypticase soy broth (TSB) (Oxoid) and incubated at 180rpm for 24 hours in a 37℃ incubator. Bacteria in the late logarithmic growth phase were used for further experiments. S. aureus ATCC25923 and RN4220 were obtained from the American Type Culture Collection (ATCC) and used as reference strains or used for phage titration. S. aureus clinical isolates were identified by an independent pathology laboratory and stored at -80°C. The E. coli expression strain (E4643) was an E. coli made in
Shearwin Laboratory from E4640+ (Shearwin K., School of Biological Sciences, University of Adelaide, Adelaide, SA, Australia). [00139] Phages and phage titer determination Two strictly lytic S. aureus phages (APTC-SA-2 and APTC-SA-12; Adelaide Phage Therapy Centre, Adelaide, SA, Australia) were used for all experiments. The phages were identified as being of the genus Kayvirus, subfamily Twortvirinae, family Herelleviridae. Phage titers were determined against S. aureus RN4220 (ATCC) using the double layer spot assay (DLSA). Briefly, 100 μl of an RN4220 overnight culture was mixed with 4 mL of 0.4% TSA and poured onto a 1.5 % TSA plate. After 20 minutes, serially diluted samples of phage were spotted onto the double layer agar plates in 3 μl/spot in triplicates. Plaques were counted after overnight incubation at 37°C, and phage titers were calculated based on the dilution. [00140] Phage sensitivity test Sensitivity tests of S. aureus clinical isolates was performed as described previously (Drilling et al., 2014 supra). Briefly, 200 μl of an overnight S. aureus culture was spread onto Columbian blood agar plates (Oxoid) and then the plates were incubated at 37°C for 1 hour.5 µl diluted phage (106 PFU/ml) were spotted onto the plates in triplicates. Phage buffer solution (SM buffer and TSB) was spotted in the centre of the plates as a negative control. Phage sensitivity was determined as previously described after overnight incubation at 37°C (see Zhang G et al., 2018 supra). Confluent lysis zones observed on plates were defined as phage sensitive (+), semi-confluent lysis zones were defined as phage semi- sensitive (+/-), and no plaques were defined as phage insensitive (Ooi ML et al., Jama Otolaryngol 145(8):723-729, 2019). Phage sensitivity was tested three times. [00141] Clindamycin minimum inhibitory concentration (MIC) assays The MIC of clindamycin against the S. aureus strains was assessed using the broth microdilution technique as previously described (see Wiegand et al., 2008 supra). Results were interpreted as follows: Sensitive: ≤ 0.2 μg/mL; Intermediate: 0.4μg/ml; Resistant: ≥ 0.6μg/mL. The S. aureus strains sensitive to clindamycin were selected for further tests. The MIC was performed three times. [00142] Phage and clindamycin combination treatment A phage and clindamycin synergy assay was performed using 96 well plates. In brief, selected S. aureus strains (phage non-sensitive) were grown on 1.5 % TSA at 37°C overnight. A single colony was transferred to TSB to generate a culture with a starting concentration of 5 x 105 CFU/ml. Phages were added to the bacteria culture at a MOI of 1 according to phage titers. Clindamycin was added to the cultures at ½ MIC (according to the MIC assay result). Optical density (Gorski A et al., Antibiotics (Basel) 9(11), 2020) readings at 600 nm were recorded after 24 hours. Fresh TSB, S. aureus treated with ½ MIC clindamycin and S. aureus treated with phage at MOI=1 was used as a
control. [00143] Exit phage purification Briefly, S. aureus colonies (parent phage non-sensitive S. aureus strain) was transferred to 20 ml TSB with a starting concentration of 5 x 105 CFU/ml. Phage (MOI=1) and ½MIC clindamycin were added. OD 600 nm were recorded after 24 hours as described above. The mixture was then centrifuged at 4,000 rpm for 10 mins to remove bacteria and filtered using a 0.2 ^m syringe filter to sterilise. The exit phage titers were determined using DLSA as described above. [00144] Activities and specificity of exit phage The exit phage bacteriolytic activity was determined by treating parent phage non-sensitive S. aureus strains (5 x 105 CFU/ml) with corresponding exit phages at MOI=1 at 180rpm for 24 hours in a 37℃ incubator. OD 600 nm was recorded after 24 hours as described above. The exit phage specificity was tested by treating various S. aureus strains and the parent strain with exit phage at MOI=1 using the same procedure as described above. The exit phage lytic activity was investigated by treating parent phage non-sensitive S. aureus strains with corresponding exit phages at MOI=0.2, 0.1, 0.01 and 0.001 overnight as described above. All tests were repeated in 3 independent experiments. [00145] Thermal and pH stability All thermal and pH stability tests were performed three times according to a previous protocol with modifications (Camens S et al., Microorg 9(9), 2021). For the thermal stability test, phages (109 pfu/mL) were incubated at different temperatures (40; 50; 60; 70 and 80°C) for 1 h. For the pH stability tests, phages (109 PFU/mL) were diluted 100-fold with SM buffer with different pH values (range from 3 to 12) and incubated for 1 h at room temperature. The phage titers were then determined using DLSA as described above. [00146] One-step growth curve One-step growth curve was performed as detailed previously (Chang Y et al., Viruses 7(10):5225- 5242, 2015). Briefly, 100 μL phages (1× 108 PFU/mL) were mixed with 1 mL S. aureus (1.5 x 108 CFU/mL) culture at a MOI of 0.1 in 8.9 mL TSB and incubated at 37 ℃ for 5 min. The mixture was then centrifuged, and the pellets were resuspended in 9.9 mL fresh TSB. The resuspended pellets were incubated at 37 ℃ with shaking at 180 rpm.100 μL mixture was taken every 30 min. The mixture was centrifuged at 13,000 g for 5 min, and the titres of the phage were determined using the DLSA. The experiments were carried out in triplicates. [00147] Measurement of frequency of bacteriophage-insensitive mutants (BIMs) The frequency of BIMs was performed by treating an overnight culture of S. aureus (approximately 109 CFU/ml) with S. aureus entry and exit phage at a MOI of 100. CaCl2 (10mM) and MgSO4 (10mM)
were added to the mixture at final concentration at 10mM. Then the mixture was incubated at 370C for 10 min. After 10 min, the mixture left at room temperature to allow cool down. The serial diluted mixtures were plated (20ul/spot) in triplicates and incubated overnight at 370C. The colonies were counted and calculated. The BIM frequency was determined as surviving viable counts divided the initial viable counts. All the experiments were performed three times. [00148] Construction of E. coli expressing phage proteins and PHEARLESS assay A system, termed PHEARLESS (phage-based expression, amplification, and release of lytic enzyme species), was used to express phage proteins of interest in E. coli comprising three components engineered into the E. coli expression strain (E4643), namely (1) the integrated cumate inducible 186tum induction module, (2) the engineered 186∆tum prophage genome and (3) the protein expression plasmid. The E.coli containing the target protein expression plasmids were streaked out on LB agar plates with spectinomycin (50μg/mL; Sigma Aldrich, Bayswater, VIC, Australia) and the S. aureus strains C319, C244, C330, C43, C259 and ATCC29923, were streaked out on LB agar plates. The plates were incubated at 37 ℃ degrees overnight. A single colony of the E. coli expression strain was picked to grow in LB broth with spectinomycin (50μg/mL) overnight to generate a fresh bacterial culture. Similarly, a single colony of each of the S. aureus strains was picked to grow in LB broth overnight. The next day, 400 µL of the bacterial cultures was then diluted into 25 ml fresh LB broth and kept at 37 ℃ degrees with shaking at 180 rpm. LB agar plates with 120 µM cumate (cumic acid; Sigma Aldrich) were prepared.200 µL of the broth culture of the target S. aureus strains (C319, C244, C330, C43, C259 and ATCC29923) was mixed with 3 ml 0.7% molten agar containing 120 µM cumate, and was poured onto the top of the LB plates. Plates were left to dry. Once the E. coli broth cultures reached OD600 nm of 0.6~0.7, the broth culture was centrifuged at 5,000 rpm for 5 min and the supernatant removed. The pellets were resuspended in fresh LB broth, serially diluted and spotted onto the target S. aureus bacterial lawn. The plates were then left to dry and incubated at 37℃ degrees overnight to allow cell lysis. The plasmid containing an "empty" protein expression construct was used as negative control. [00149] Results [00150] Phage sensitivity test A total of 60 S. aureus clinical isolates were tested for their phage sensitivity in order to select those that were insensitive to both lytic APTC-SA-2 and APTC-SA-12 S. aureus phage. Among those 60 clinical isolates, four strains (C43, C319, C285 and C330) were considered phage non-sensitive since no plaques were observed. Moreover, MIC assays indicated that all four of these strains were sensitive to clindamycin. ATCC25923 was used as a reference control strain and was sensitive to both phage strains and to clindamycin. The results of the phage and clindamycin sensitivity tests are shown in Table 3.
[00151] Table 3: Phage host range and antibiotic sensitivity + =
phage sensitive; - = phage resistant. [00152] Phage non-sensitive S. aureus is sensitised to phage by low concentration clindamycin Four phage non-sensitive S. aureus strains (C43, C330, C285 and C319) were selected to be treated with the APTC-SA-2 and APTC-SA-12 phage combined with ½ MIC clindamycin. The combination treatment could kill the bacteria after 24 hours and was significantly more effective than control (ie bacteria with TSB), or treatment with ½ MIC clindamycin and phage only. The growth of S. aureus bacteria was similar among control, ½ MIC clindamycin treated, and phage only treated groups (see Figure 6A-B, D-E). ATCC 25923 was sensitive to both phage types, and phage in combination with ½ MIC clindamycin were equally effective at killing this strain compared to no-treatment control and to ½ MIC clindamycin (Figure 6C and F). [00153] Exit phage bactericidal activity To evaluate whether the progeny phage particles (exit phage), produced after sensitisation of non- sensitive S. aureus strains with ½ MIC clindamycin and adding the entry phage (APTC-SA-2 and APTC-SA-12), were effective at killing their own parent strain, exit phage particles were purified for both APTC-SA-2 or APTC-SA-12 entry phage after they went through an infection cycle of two representative non-sensitive S. aureus strains. Compared with positive control (TSB) and entry phage treatment (APTC-SA-2 or APTC-SA-12), it was found that the exit phage could significantly reduce the viability of parent strains in the absence of ½ MIC clindamycin at MOI=1 (Figure 7). [00154] Exit phage specificity and lytic activity To further investigate the specificity of the exit phage, the exit phage APTC-SA-2-C43, APTC-SA-2- C330, APTC-SA-2-C285, and APTC-SA-2-C319 were used to treat phage non-sensitive S. aureus clinical isolates C43, C330, C285, and C319 at MOI=1. The results, shown in Figure 8 A-D, indicated that the exit phages were active against their parent strain but not against any of the other isolates. Next, the lytic activity of the exit phage was tested (and compared to the entry phage), and this showed that the exit phage could infect the parent strain at a MOI as low as 0.001. Moreover, CFU counts
showed the presence of < 67 CFU/mL, indicating S. aureus eradication when the parent strain was treated with the exit phage at MOI as low as 0.001. [00155] Exit phage characterisation The phage temperature stability, pH stability and one-step growth curve for entry and exit phages were evaluated and compared. In comparison with APTC-SA-2, the exit phage APTC-SA-2-C43 and APTC-SA-2-C330’s temperature stability and pH stability were similar. With the one-step growth curves, it was found that the entry phage and exit phage showed similar latency time and burst size (Figure 9A-C). Similar results were noted when comparing the results obtained from the entry phage APTC-SA-12 with the exit phage APTC-SA-12-C285 and APTC-SA-12-C319. [00156] The frequency of BIMs of entry phage and exit phage have been determined. Results showed the frequency of BIM generation by the exit phage was lower compared with their corresponding entry phage (Table 4). [00157] Table 4: Frequency of emergence of phage insensitive mutants (BIMs) of entry phage and exit phage
*Experiment performed using manufacturing strain C16 (S. aureus). The average of three independent experiments is shown. [00158] PHEARLESS assay The PHEARLESS assay described above was conducted to investigate the lytic activity of the exit phage. In particular, the assay was conducted to investigate and compare the lytic activity of the lysin protein of the entry phage (LysK) with that of the exit phage (denoted mLysK). Briefly, exit phage mLysK expression constructs were prepared from APTC-SA-2-C330 and from APTC-SA-2-C319 and an entry phage LysK expression construct was prepared from APTC-SA-2. All expression constructs were transformed into the PHEARLESS system and tested against the S. aureus phage non-sensitive
strains C319, C285, C330 and C43 and also against the phage sensitive ATCC25923 to evaluate their ability to facilitate bacterial lysis. The entry phage LysK only showed weak lytic activity against ATCC25923 as a zone of clearing was observed at the highest dosage only, whilst all other strains remained unaffected by the entry phage LysK. In contrast, the expressed exit phage mLysK from APTC-SA-2-C330 (298) and from APTC-SA-12-C319 (294) showed lytic activity against all of the tested strains in a dose-dependent way (zone of clearing appearance clear to blurred from highest dosage to lowest dosage). Images of representative plates showing the lytic activity of APTC-SA-2- C330 (298) and from APTC-SA-12-C319 (294) on S. aureus strain C19 is shown in Figure 10. [00159] These results demonstrate that the exit phage contained a modified lysin protein, and as such the exit phage encodes an endopeptidase with modified activity and/or target specificity. Further, sequencing of the LysK gene from the exit phage demonstrated that the exit phage contained at least a mutation in the lysin gene which produces the modified lysin protein. [00160] Discussion [00161] To date no strategies have been reported that can sensitise S. aureus and MRSA phage resistant strains to phage. Consequently, patients infected with such strains are excluded from phage therapy with few or no therapeutic options remaining to treat those often-devastating infections. Here, it was found that two lytic S. aureus phages, when used to treat four non-sensitive S. aureus clinical isolates in combination with ½ MIC clindamycin, could significantly reduce the growth of the insensitive S. aureus clinical isolates. Further, it was found that the harvested and purified exit phage were able to re-infect the parent S. aureus strains (only), without the help of clindamycin, and with at least a 1000-fold higher level of lytic activity. Together with characterisation that showed that the stability and one-step growth curve of the exit phage showed no significant difference with the corresponding entry phage, these results indicate that these exit phage could be useful in treating infections of phage insensitive S. aureus strains in patients. [00162] Throughout the specification and the claims that follow, unless the context requires otherwise, the words "comprise" and "include" and variations such as "comprising" and "including" will be understood to imply the inclusion of a stated integer or group of integers, but not the exclusion of any other integer or group of integers. [00163] The reference to any prior art in this specification is not, and should not be taken as, an acknowledgement of any form of suggestion that such prior art forms part of the common general knowledge.
[00164] It will be readily appreciated by those skilled in the art that methods, phage and phage proteins of the present disclosure are not restricted in their use to the particular application described. Neither are the methods, phage and phage proteins restricted in their preferred embodiment(s) with regard to the particular elements and/or features described or depicted herein. Further, it will be readily appreciated that the methods, phage and phage proteins are not limited to the embodiment(s) disclosed, but are capable of numerous rearrangements, modifications and substitutions without departing from the scope of the present disclosure.
Claims
CLAIMS: 1. A method of producing a modified phage, said method comprising the steps of: (i) treating a host bacteria insensitive to a selected phage strain with a suitable amount of the said phage strain and at least one antibacterial agent comprising protein synthesis inhibitory activity, and culturing the bacteria for a period and under conditions suitable for the phage to infect the bacteria and replicate to generate progeny phage; and (ii) recovering and expanding progeny phage which are phage with a modified capability to infect and cause lysis of said host bacteria.
2. A method according to claim 1 for producing a modified phage for use in a phage therapy of an infection in a subject, wherein said method comprises the steps of: (i) treating a host bacteria that has been isolated from the said subject and which is insensitive to a selected phage strain with a suitable amount of the said phage strain and at least one antibacterial agent comprising protein synthesis inhibitory activity, and culturing the bacteria for a period and under conditions suitable for the bacteriophage to infect the bacteria and replicate to generate progeny phage; (ii) recovering and expanding progeny phage which are phage with a modified capability to infect and cause lysis of said host bacteria; and (iii) providing the modified phage of step (ii) in a pharmaceutical composition for administration to the said subject.
3. A method according to claim 1 or 2, wherein the host bacteria is selected from the group consisting of Staphylococcus species, Streptococcus species, Enterococcus species, Corynebacterium species, Bacteriodes species, Bacillus species, Yersinia species, Legionella species, Francisella species, Salmonella species, Mycobacterium species, Acinetobacter species, Clostridium species, Pseudomonas species, and Entobacteriaceae species.
4. A method according to any one of the preceding claims, wherein the host bacteria is selected from the group consisting of S. aureus, S. epidermidis, S. lugdunensis, Acinetobacter baumannii, Clostridium difficile, and Pseudomonas aeruginosa.
5. A method according to any one of the preceding claims, wherein the host bacteria is an antibiotic-resistant bacteria.
6. A method according to any one of the preceding claims, wherein the host bacteria is a multidrug-resistant (MDR) bacteria.
7. A method according to any one of the preceding claims, wherein the host bacteria is a clinical isolate.
8. A method according to any one of the preceding claims, wherein the host bacteria is a clinical isolate from a bacterial infection characterised by the presence of a bacterial biofilm.
9. A method according to any one of the preceding claims, wherein the host bacteria is treated in step (i) with a phage strain (entry phage) selected from a phage bank.
10. A method according to any one of the preceding claims, wherein the at least one antibacterial agent comprising protein synthesis inhibitory activity is provided at an amount that is sub-inhibitory.
11. A method according to any one of the preceding claims, wherein the antibacterial agent is selected from one or more of the group consisting of erythromycin, clindamycin and azithromycin.
12. A method according to any one of the preceding claims, wherein step (ii) comprises two or more steps of culturing the host bacteria in the presence of the progeny phage (exit phage) to expand the phage number.
13. A method according to any one of the preceding claims, wherein the modified phage of step (ii) show an enhanced level of lytic activity against the host bacteria that is at least 500-fold higher than that of the selected entry phage.
14. A method of treating a bacterial infection in a subject, said method comprising the steps of: 1. obtaining a sample of a bacteria causative of an infection in said subject, 2. treating the bacteria with a suitable amount of a selected phage strain to which the bacteria is insensitive and at least one antibacterial agent comprising protein synthesis inhibitor activity, and culturing the bacteria for a period and under conditions suitable for the bacteriophage to infect the bacteria and replicate to generate progeny phage; 3. recovering and expanding progeny phage which are phage with a modified capability to infect and cause lysis of said bacteria; and 4. administering to the subject an effective amount of the modified phage of step 3, or a further propagated form thereof, to treat the infection.
15. A method according to claim 14, wherein the host bacteria is selected from the group consisting of Staphylococcus species, Streptococcus species, Enterococcus species, Corynebacterium species, Bacteriodes species, Bacillus species, Yersinia species, Legionella species, Francisella species, Salmonella species, Mycobacterium species, Acinetobacter species, Clostridium species, Pseudomonas species, and Entobacteriaceae species.
16. A method according to claim 14 or 15, wherein the host bacteria is selected from the group consisting of S. aureus, S. epidermidis, S. lugdunensis, Acinetobacter baumannii, Clostridium difficile, and Pseudomonas aeruginosa.
17. A method according to any one of claims 14 to 16, wherein the bacteria causative of the infection is an antibiotic-resistant bacteria.
18. A method according to any one of claims 14 to 17, wherein the bacteria causative of the infection is a multidrug-resistant (MDR) bacteria.
19. A method according to any one of claims 14 to 18, wherein the bacterial infection is characterised by the presence of a bacterial biofilm.
20. A method according to any one of claims 14 to 19, wherein the bacteria is treated in step 2 with a phage strain (entry phage) selected from a phage bank.
21. A method according to any one of claims 14 to 20, wherein the at least one antibacterial agent comprising protein synthesis inhibitory activity is provided at an amount that is sub-inhibitory.
22. A method according to any one of claims 14 to 21, wherein the antibacterial agent is selected from one or more of the group consisting of erythromycin, clindamycin and azithromycin.
23. A method according to any one of claims 14 to 22, wherein step 3 comprises two or more steps of culturing the bacteria in the presence of the progeny phage (exit phage) to expand the phage number.
24. A method according to any one of claims 14 to 23, wherein the modified phage of step 3 show an enhanced level of lytic activity against the bacteria that is at least 500-fold higher than that of the selected entry phage.
25. A method according to any one of claims 14 to 24, wherein the modified phage of step 4, or a further propagated form thereof, are provided as a pharmaceutical composition to treat the infection.
26. A method according to any one of claims 14 to 25, wherein the modified phage, or a further propagated form thereof, are used in a combination therapy with a suitable antibacterial agent to treat the infection.
27. A method according to any one of claims 14 to 26, wherein the bacterial infection is associated with a sinus infection, a skin ulcer, a skin infection, or a lung infection.
28. A modified phage produced in accordance with the method of any one of claims 1 to 13, or a further propagated form thereof.
29. A pharmaceutical composition comprising a modified phage produced in accordance with the method of any one of claims 1 to 13 or a further propagated form thereof, optionally in combination with at least one pharmaceutically acceptable carrier, diluent and/or excipient.
30. A pharmaceutical composition according to claim 29 for topical administration, for delivery via a gel, or for pulmonary delivery.
31. The use of a modified phage produced in accordance with any one of claims 1 to 13 or a further propagated form thereof, in the manufacture of a medicament for treating an infection in a subject.
32. A modified phage, produced in accordance with the method of any one of claims 1 to 13, or a further propagated form thereof, for treating an infection in a subject.
33. A method of killing bacteria, said method comprising contacting the bacteria with a modified phage produced in accordance with the method of any one of claims 1 to 13, or a propagated form thereof.
34. An isolated phage lysin protein derived from a modified phage produced in accordance with the method of any one of claims 1 to 13.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2022901885 | 2022-07-05 | ||
AU2022901885A AU2022901885A0 (en) | 2022-07-05 | Method of production and treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024007055A1 true WO2024007055A1 (en) | 2024-01-11 |
Family
ID=89454662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2023/050622 WO2024007055A1 (en) | 2022-07-05 | 2023-07-05 | Method of production of modified phage and method of treatment using same |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024007055A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009068858A1 (en) * | 2007-11-26 | 2009-06-04 | Plant Bioscience Limited | Novel polypeptides having endolysin activity and uses thereof |
WO2013170022A1 (en) * | 2012-05-09 | 2013-11-14 | Contrafect Corporation | Biofilm prevention, disruption and treatment with bacteriophage lysin |
-
2023
- 2023-07-05 WO PCT/AU2023/050622 patent/WO2024007055A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009068858A1 (en) * | 2007-11-26 | 2009-06-04 | Plant Bioscience Limited | Novel polypeptides having endolysin activity and uses thereof |
WO2013170022A1 (en) * | 2012-05-09 | 2013-11-14 | Contrafect Corporation | Biofilm prevention, disruption and treatment with bacteriophage lysin |
Non-Patent Citations (8)
Title |
---|
AKTURK ERGUN, OLIVEIRA HUGO, SANTOS SÍLVIO B., COSTA SUSANA, KUYUMCU SULEYMAN, MELO LUÍS D. R., AZEREDO JOANA: "Synergistic Action of Phage and Antibiotics: Parameters to Enhance the Killing Efficacy Against Mono and Dual-Species Biofilms", ANTIBIOTICS (BASEL, SWITZERLAND) 2015, vol. 8, no. 3, pages 103, XP093128101, ISSN: 2079-6382, DOI: 10.3390/antibiotics8030103 * |
ARIAS‐SÁNCHEZ F. I., ALLEN R. C., HALL A. R.: "Effects of prior exposure to antibiotics on bacterial adaptation to phages", JOURNAL OF EVOLUTIONARY BIOLOGY, JOHN WILEY & SONS, INC., HOBOKEN, USA, vol. 31, no. 2, 1 February 2018 (2018-02-01), Hoboken, USA, pages 277 - 286, XP093128094, ISSN: 1010-061X, DOI: 10.1111/jeb.13220 * |
BURROWES, B. ET AL.: "Directed in Vitro Evolution of Therapeutic Bacteriophages: The Appelmans Protocol", VIRUSES, vol. 11, no. 3, 2019, pages 241, XP055759309, Retrieved from the Internet <URL:http://dY.doi.org/10.3390/v11030241> DOI: 10.3390/v11030241 * |
ESKENAZI ANAÏS, LOOD CÉDRIC, WUBBOLTS JULIA, HITES MAYA, BALARJISHVILI NANA, LESHKASHELI LIKA, ASKILASHVILI LIA, KVACHADZE LEILA, : "Combination of pre-adapted bacteriophage therapy and antibiotics for treatment of fracture-related infection due to pandrug-resistant Klebsiella pneumoniae", NATURE COMMUNICATIONS, NATURE PUBLISHING GROUP, UK, vol. 13, no. 1, UK, XP093128097, ISSN: 2041-1723, DOI: 10.1038/s41467-021-27656-z * |
FRIMAN V‐P., SOANES‐BROWN D., SIEROCINSKI P., MOLIN S., JOHANSEN H. K., MERABISHVILI M., PIRNAY J‐P., DE VOS D., BUCKLING A.: "Pre‐adapting parasitic phages to a pathogen leads to increased pathogen clearance and lowered resistance evolution with Pseudomonas aeruginosa cystic fibrosis bacterial isolates", JOURNAL OF EVOLUTIONARY BIOLOGY, JOHN WILEY & SONS, INC., HOBOKEN, USA, vol. 29, no. 1, 1 January 2016 (2016-01-01), Hoboken, USA, pages 188 - 198, XP093128099, ISSN: 1010-061X, DOI: 10.1111/jeb.12774 * |
KELLY, D. ET AL.: "Development of a broad-host-range phage cocktail for biocontrol", BIOENGINEERED BUGS, vol. 2, no. 1, 2011, pages 31 - 37, XP002691347, Retrieved from the Internet <URL:https://doi.org/10.4161/bbug.2.1.13657> DOI: 10.4161/BBUG.2.1.13657 * |
LIU SHA, ZHAO YIN, HAYES ANDREW, HON KAREN, ZHANG GUIMIN, BENNETT CATHERINE, HU HUA, FINNIE JOHN, MORALES SANDRA, SHEARWIN LINDA, : "Overcoming bacteriophage insensitivity in Staphylococcus aureus using clindamycin and azithromycinat subinhibitory concentrations", ALLERGY, WILEY-BLACKWELL PUBLISHING LTD., UNITED KINGDOM, vol. 76, no. 11, 1 November 2021 (2021-11-01), United Kingdom , pages 3446 - 3458, XP093128092, ISSN: 0105-4538, DOI: 10.1111/all.14883 * |
NIKOLICH, M. P. ET AL.: "Bacteriophage Therapy: Developments and Directions", ANTIBIOTICS, vol. 9, no. 3, 2020, pages 135, XP055975637, Retrieved from the Internet <URL:http://dx.doi.org/10.3390/antibiotics9030135> DOI: 10.3390/antibiotics9030135 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hraiech et al. | Bacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: rationale and current status | |
Kelly et al. | Development of a broad-host-range phage cocktail for biocontrol | |
CN108135971A (en) | The thus purposes of the antibacterial activity of antibiotic that lysin recovery/enhancing inhibits in the presence of pulmonary surfactant | |
US20220370526A1 (en) | Phage compositions comprising crispr-cas systems and methods of use thereof | |
JP2022062116A (en) | Therapeutic bacteriophage compositions | |
Rezk et al. | Bacteriophage as a potential therapy to control antibiotic-resistant Pseudomonas aeruginosa infection through topical application onto a full-thickness wound in a rat model | |
Lin et al. | The antibacterial effects of an antimicrobial peptide human β-defensin 3 fused with carbohydrate-binding domain on Pseudomonas aeruginosa PA14 | |
Liu et al. | Overcoming bacteriophage insensitivity in Staphylococcus aureus using clindamycin and azithromycinat subinhibitory concentrations | |
Laure et al. | Phage resistance-mediated trade-offs with antibiotic resistance in Salmonella Typhimurium | |
Asghar et al. | Genomic characterization of lytic bacteriophages A¥ L and A¥ M infecting ESBL K. pneumoniae and its therapeutic potential on biofilm dispersal and in-vivo bacterial clearance | |
US20220389392A1 (en) | Crispr cas systems and lysogeny modules | |
WO2024007055A1 (en) | Method of production of modified phage and method of treatment using same | |
WO2021115415A1 (en) | Methods for treating bacterial infections | |
Wojnicz et al. | Influence of subinhibitory concentrations of amikacin and ciprofloxacin on morphology and adherence ability of uropathogenic strains | |
Leone et al. | Severe bacterial infections in haemodialysis patients | |
Liu et al. | Study of Combined Effect of Bacteriophage vB3530 and Chlorhexidine on the Inactivation of Pseudomonas aeruginosa | |
US20240011041A1 (en) | Phage compositions for pseudomonas comprising crispr-cas systems and methods of use thereof | |
Qasemi et al. | Bacterial Resistance of Acinetobacter baumannii: A Global Concern | |
EP4265264A1 (en) | Bacteriophages suitable for treating a bacterial infection caused by klebsiella pneumoniae | |
TW202305126A (en) | Phage compositions for pseudomonas comprising crispr-cas systems and methods of use thereof | |
Nawaz et al. | Phage Therapy as a revolutionary treatment for Multidrug-resistant Pseudomonas aeruginosa infections; A Narrative review | |
Al-Anany et al. | Temperate Phage-Antibiotic Synergy Eradicates Bacteria Through Depletion of Lysogens | |
Boncompagni | Development of novel antimicrobial strategies and surveillance program to fight antimicrobial resistance | |
Li et al. | The role of type VI secretion system genes in antibiotic resistance and virulence in Acinetobacter baumannii clinical isolates | |
JP2023548580A (en) | Phage compositions against Escherichia including CRISPR-CAS system and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23834318 Country of ref document: EP Kind code of ref document: A1 |